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ABSTRACT
The "classic" prostate cell lines, DU145, PC-3 and LNCaP, have served as a valuable
cell biological model for research into prostate cancer. However, their relevance may
be limited because they derive from metastatic, and not from primary normal and
tumour epithelium. The cell lines (1532T, 1535T, 1542T, 1542N and BPH-l) have
been derived from primary benign and malignant human tumour prostate epithelium
and may be more representative. Using these cell lines I have examined the role of
basic cell damage responses (repair, checkpoint activation, apoptosis and associated
signalling proteins, and the influence of androgen status) in cell inactivation, and its
relevance to treatment.
Numerous studies have suggested that loss of p53 function leads to resistance to
chemotherapeutic agents and irradiation. It is shown here that the p53-inactive cell
lines are, in fact, the most sensitive to chemotherapeutic agents such as etoposide,
vinblastine and estramustine, whilst the p53 wild-type cell line, LNCaP, is the most
radiosensitive. Notwithstanding the effects of p53 degradation by the HPV -16 E6
viral protein, the results on chemosensitivity raises the possibility that different
chemotherapeutic agents may have different p53-dependent effects in different
tumour cells.
Androgen deprivation is demonstrated to sensitise prostate cancer cells to
chemotherapeutic agents and it is shown that the hormone independent cell lines are
the most chemosensitive. The LNCaP cell line displayed an increased resistance to
apoptosis induced by etoposide and gamma irradiation, suggesting that androgens are
capable of protection against both these DNA damaging agents.
The major factors determining radiosensitivity in human tumour cell lines are known
to be DNA double-strand break (dsb) induction and repair. In the prostate cell lines I
find that cellular radiosensitivity correlates with the number of DNA double-strand
breaks measured within 2 hours of irradiation, and that the more radioresistant cell
lines show better repair competence. Conclusions as to the influence of androgen
Stellenbosch University http://scholar.sun.ac.za
III
dependence on radiosensitivity and repair are not possible at this stage since only the
LNCaP cell line was androgen sensitive. The fact that the 2 hour repair period can
separate radiosensitive from radioresistant cells in 2 groups of human tumour cell
lines highlights the role of non-homologous end-joining repair. This has implications
for therapy, and is consistent with the clinical observation that prostate tumours can
be successfully controlled by low dose rate-brachytherapy.
To evaluate the role of apoptosis, cells were exposed to TD50 concentrations of
chemotherapeutic drugs, and 60Co y-irradiation. Apoptosis was found to be low,
overall, and ranged from 0.1% - 12.1%,3.0% - 6.0% and 0.1% - 8.5% for etoposide,
estramustine and vinblastine, respectively. The percentage of cells undergoing drug-
induced apoptosis was, on average, higher in the tumour cell lines than in the normal
cell lines. Gamma irradiation-induced apoptosis levels ranged from 1.3% - 7%. The
LNCaP cell line yielded the lowest percentage of apoptotic cells after exposure. The
l532T cell line yielded the highest percentage of apoptotic cells after exposure.
Apoptotic propensity did not rank the cell lines according to their radiosensitivity.
Immunoblotting demonstrated that the apoptosis-associated proteins, bax and bcl-2,
are expressed at a basal level in all the cell lines tested, but no increase was detected
after exposure to TD50 doses of etoposide, vinblastine and estramustine. The ratio of
bax and bcl-2 also was not altered by DNA damage.
No evidence was found that a correlation may exist between reproductive cell death
and the expression of genes which control apoptosis. My results show that apoptosis
is not a major mechanism of drug- or radiation-induced cell death in prostate cell
lines.
In conclusion, loss of p53 function and loss of androgen dependence was not found to
be correlated with resistance of tumours to chemotherapeutic drugs. Cellular
radiosensitivity was found to be correlated with the number of DNA double-strand
breaks remaining after 2 hours of repair. The more radioresistant cell lines showed
better repair competence. Apoptosis and genes affecting apoptosis, such as p53 and
members of the bcl-2 family, do not seem to contribute significantly to the sensitivity
of prostate cancer cells to anticancer drugs and irradiation.
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ABSTRAK
Die klassieke prostaat sellyne, DU145, PC-3 en LNCaP, het 'n waardevolle bydrae
gemaak in die sel biologiese model in prostaat kanker. Die toepaslikheid daarvan
mag egter beperk wees, aangesien hierdie sellyne afkomstig is van metastatiese, en
nie van primêr normale en tumor epiteel nie. Die sellyne 1532T, 1535T, 1542T,
1542N en BPH-I is afkomstig van primêre benigne en maligne menslike prostaat
tumor epiteel en mag moontlik meer verteenwoordigend wees. Deur van hierdie
sellyne gebruik te maak, is die rolondersoek van die reaksie op basiese selskade
(d.w.s. herstel, beheerpunt aktivering, apoptose en verwante sein proteïene, en die
invloed van androgeen status) tydens die proses van sel inaktivering, asook die
toepaslikheid ten opsigte van behandeling.
Volgens verskeie studies lei die verlies aan p53 funksie tot weerstandigheid teen
chemoterapeutiese middels en bestraling. Die resultate van hierdie studie toon dat die
p53-onaktiewe sellyne egter die sensitiefste is vir chemoterapeutiese middels, soos
etoposied, vinblastien en estramustien, terwyl die p53 natuurlike-tipe sellyn, LNCaP,
die meeste radiosensitief is. Ten spyte van die invloed van p53 afbraak deur die
HPV -16 E6 virale proteïen, dui die resultate van chemosensitiwiteit op die
moontlikheid dat verskillende chemoterapeutiese middels verskillende p53-afhanklike
effekte op verskillende tumorselle mag hê.
Dit is bewys dat onttrekking van androgeen prostaat kankerselle sensitiseer teen
chemoterapeutiese middels en dat hormoon-onafhanklike sellyne die hoogste
chemosensitiwiteit vertoon. Die LNCaP sellyn vertoon 'n verhoogde weerstandigheid
teen apoptose wat deur etoposied en y-bestraling geïnduseer is, wat 'n aanduiding is
dat androgene beskerming kan bied teen beide hierdie DNA beskadigingsfaktore.
Die belangrikste faktore wat die radiosensitiwiteit in menslike tumorselle bepaal, IS
bekend dat dit die dubbelbande van DNA verbreek en herstel. Hierdie studie het
aangetoon dat in prostaat sellyne die sellulêre radiosensitiwiteit korreleer met die
aantal DNA dubbelband verbrekings binne 2 uur na bestraling, en dat die meer
radioweerstandige sellyne beter herstelvermoë vertoon. Gevolgtrekkings oor die
Stellenbosch University http://scholar.sun.ac.za
vinvloed van androgeen se afhanklikheid van radiosensitiwiteit en herstel kan egter nie
op hierdie stadium gemaak word nie, aangesien slegs die LNCaP sellyn androgeen-
afhanklik was. Die feit dat die 2 uur herstelperiode 'n skeiding kan maak tussen
radiosensitiewe en radioweerstandige selle in twee groepe menslike tumor sellyne,
onderstreep die rol van herstel van nie-homoloë endverbindings. Dit hou implikasies
in vir terapie, en stem ooreen met die kliniese waarnemings dat prostaat tumore
suksesvol gekontroleer kan word deur lae intensiteit dosis bragiterapie.
Ten einde die rol van apoptose te ondersoek, is selle blootgestel aan TD50
konsentrasies chemoterapeutiese middels, asook 60Coy-bestraling. Apoptose was oor
die algemeen laag, en het gestrek van 0.1% tot 12.1%,3.0% tot 6.0% en 0.1% tot
8.5% vir etoposied, estramustien en vinblastien onderskeidelik. Die persentasie selle
wat middel geïnduseerde apoptose ondergaan het, was gemiddeld hoër in tumor
sellyne as in normale sellyne. Die waardes van apoptose geïnduseer deur y-bestraling
het gewissel van 1.3% tot 7.0%. Die LNCaP sellyn het die laagste persentasie
apoptotiese selle na bestraling gelewer, terwyl die 1532 r sellyn die hoogste
persentasie gelewer het. Die volgorde van die radiosensitiwiteit van die sellyne was
nie waarneembaar in hulle geneigdheid tot apoptose nie. Immunoblots het aangetoon
dat die apoptose-geassosieerde proteïene, bax en bcl-2, uitgeskei word teen 'n
basisvlak in al die sellyne wat getoets is, maar dat geen verhoogde uitskeiding
waarneembaar was na blootstelling aan TD50 dosisse etoposied, vinblastien en
estramustien nie. Die verhouding van bax en bcl-2 is ook nie beïnvloed deur DNA
beskadiging nie.
Dit blyk daarom dus onwaarskynlik dat daar 'n korrelasie bestaan tussen
reproduktiewe seldood en die uitskeiding van gene wat apoptose beheer. Die resultate
dui daarop dat apoptose me 'n belangrike meganisme vir middel- of
bestralingsgeïnduseerde seldood in prostaat sellyne is nie.
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1CHAPTERl
INTRODUCTION
Prostate cancer - the clinical problem
Prostate cancer is the second most common cancer in South African men, with an
estimated annual incidence of 19.1 per 100 000 men (Sitas 1994). However, this
incidence rate is probably deceptively low owing to incomplete reporting of cases.
Comparison of the incidence of prostate cancer in the different racial groups shows
that it is the second most common malignancy in Caucasian, African, and so-called
Coloured (Mixed race), and the fourth most common malignancy in Asian men in
South Africa (Sitas 1994). Prostate cancer is the most frequently diagnosed
malignancy and the second leading cause of cancer-related deaths among men m
Western industrialised countries (Miyake et aI2001).
Prostate cancer is often found incidentally during transurethral resection of the
prostate, which is performed to relieve obstruction normally associated with benign
prostatic hyperplasia. Since the incidence of prostate cancer increases as a function of
age, there is a misconception that it is a disease of the very elderly. However,
approximately 20% of prostate cancers occur in men under the age of 65 years
(Boring et al 1994). While the majority of prostate cancer cases occur in men over
the age of 65 years, the impact of the disease is still significant.
The clinical course of the disease is difficult to predict. About 50% of men with
prostate cancer have clinically advanced (ie. extra-prostatic) disease at the time of
initial diagnosis. 15% of those with organ-confined disease actually have
micrometastatie disease at the time of surgery (Carter and Coffey 1988). In some
patients, prostatic cancer metastasises rapidly, killing the patient within a year of
diagnosis. Other men survive untreated for many years with localised disease, with
no clinically detectable metastases (Johannson 1980). If completely localised (ie.
within the prostatic capsule) prostatic cancer can be cured by surgery alone (ie. radical
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2prostatectomy) (Walsh and Jewett 1980). However, when the disease IS extra-
prostatic, it is usually fatal and there is no curative treatment.
Treatment of prostate cancer
The traditional goal in the treatment of genitourinary cancer has been to maximise
patient survival. Recent advances in urologic oncology have had a positive impact on
prognosis, permitting many patients to live significantly longer with their disease.
When critically evaluating interventions in these patients it must be remembered that
cancer affects both quantity and quality of life. The goal of treatment (curative,
palliative), the treatment-associated morbidity, and not least, patient preference must
be considered when therapy decisions are made.
Complications after treatment of prostate cancer are well documented. The major
concerns of most patients are urinary incontinence and impotence (deKernion et al
1998).
Until effective systemic treatments can be developed, the best hope of decreasing the
mortality rate from prostate cancer lies in curative treatment while the tumour is still
organ-confined. The treatment choices for localised prostate cancer are limited and
include either radiotherapy or radical prostatectomy. Neither of these treatment
choices has demonstrated clear superiority in terms of long-term cure or disease-free
survival (Hartford and Zietman 1996). Each option has distinct advantages and
disadvantages, and the final treatment decision is largely based on the preference of
the individual.
Radiation Therapy
The first and by far the most useful radiation modality currently used in the treatment
of prostate cancer is external beam radiation, using mostly high-energy photons. For
patients with true early-stage prostate cancer (stage T1-T2, and a prostate specific
antigen (PSA) level less than 15nglml) external beam radiation therapy offers a good
chance of durable tumour control or eradication (Porter and Hart 1999). Among such
patients there are no survival differences between those treated with irradiation and
those treated with surgery. Men who are more than 65 years old have little, if
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3anything, to gain from surgical management. Currently, treatment recommendations
are that younger men (less than 60 years) be considered for surgery first, although
external beam radiation remains an excellent alternative. The relative morbidities of
the two alternatives must be kept in mind when discussing treatment issues with
patients: long-term impotence or incontinence may be of great concern for a younger
patient.
For patients with locally advanced cancer (T3-T4), and a PSA level greater than
15ng/ml) radiation therapy offers effective and durable palliation, but little chance for
long-term cure (Hartford and Zietman 1996).
Chemotherapy
Most of the mortality and morbidity from prostate cancer occurs in the setting of
metastatic disease, particularly in hormone-refractory disease. Therapy is primarily
palliative and aimed at delaying the onset and progression of symptoms. Once the
disease becomes resistant to hormonal suppression, the median survival is only 12-18
months (Raghavan 1988, Crawford et al 1989, Greenlee et al 2000). Options for
therapy include secondary hormonal therapy, chemotherapy, and experimental
therapies.
The prevailing opimon for the past two decades that chemotherapy is not very
effective in advanced prostate cancer could be due to: a lack of properly designed
clinical trials, the administration of chemotherapy when the tumour burden is high,
the fact that chemotherapeutic drugs currently available in clinical use preferentially
kill rapidly proliferating cancer cells, and the significant toxicity associated with
many of the drugs (CF Heyns, personal communication).
Chemotherapy should be considered for patients in whom the potential benefits of
palliation outweigh the risks of toxicity (Sternberg and lanari 1996).
The case for chemotherapy
The historical negative view for chemotherapy (which stemmed from poor efficacy)
has now been replaced by a moderate enthusiasm. The last decade indeed has
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4witnessed a new desire to investigate the potential benefits of chemotherapy. This has
been fostered by the development of several new drug regimens to accomplish
palliative responses in hormone-refractory prostate cancer.
The ability to slow and even reverse the growth of far-advanced disease raises the
possibility that the application of this therapy earlier in the disease will have a more
significant impact on mortality.
The emergence of prostate specific antigen (PSA) as a surrogate marker of disease
burden and response of advanced prostate cancer has revolutionised the study of
chemotherapy in hormone-refractory disease. Research to investigate the wider role
of chemotherapy prior to prostatectomy or radiation therapy is currently underway.
Estramustine phosphate (EMP), an agent that combines estradiol with nitrogen
mustard, has been shown to have activity against prostate cancer cells independent of
its hormone moiety and its alkylating moiety. Originally synthesised to allow
selective delivery of the alkylating agent into oestrogen receptor-positive cancer cells,
it has been shown to have little alkylating activity and acts by binding to microtubules
and the nuclear matrix. The significance of the interaction is unknown, however, and
it was postulated that EMP may bind to the nuclear matrix and interfere with the DNA
replication process (Pienta and Lehr 1993). New evidence suggests that estramustine
functions as a microtubular poison and is synergistic with multiple cytotoxic agents in
vitro and in vivo (Benson and Hartley-Asp 1990).
It is theorised that estramustine in combination with other microtubule inhibitors
(vinblastine, for example), with different sites of action, might result in an additive or
synergistic anti-tumour effect. Van Belle et al (1988) showed a greater than 50%
decline in PSA levels in 43% of patients treated with this combination in three
subsequent clinical trials. Estramustine, too, has been combined with etoposide, a
topoisomerase II inhibitor. In vitro and in vivo prostate cancer growth is
synergistically inhibited by this combination, by interaction at the nuclear matrix
(Pienta and Lehr 1993). A decline in the PSA level of more than 50% occurred in
52% of the phase II trial patients.
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5In assessing newer chemotherapy agents in the treatment of prostate cancer, it is
important to recall that the vast majority of the agents that have subsequently been
shown to have significant activity in combinations had little activity as single agents.
Androgen independence
Prostate cancer is a heterogeneous disease (Isaacs and Coffey 1981, Logothetis et al
1994). Cell lines and animal models provide important insights into the biological
basis for this heterogeneity, although our understanding of the mechanism of
androgen independence remains incomplete.
Initially, the growth of the majority of prostate cancers is androgen dependent.
Consequently, prostate cancer patients benefit temporarily from androgen-suppressing
therapies, either by surgical or chemical castration, by anti-androgens, or by a
combination of these. After an initial androgen dependent growth phase, most
prostate tumours enter an androgen independent stage. The molecular basis for this
switch from androgen dependent to androgen independent growth is largely unknown.
In the Dunning rat model engrafted prostate tumours are composed of a mixture of
androgen dependent and androgen independent cells. With castration androgen
dependent cells die and the tumour stops growing. However, androgen independent
cell growth occurs simultaneously and ultimately a palpable mass develops. Thus,
androgen ablation provides a selective advantage to androgen independent cells that
grow and eventually comprise the abundance of the tumour (Isaacs and Coffey 1981).
This scenario has been confirmed in other systems, including the human prostate
cancer cell line, LNCaP (Horoszewicz et aI1983).
Alteration in normal androgen signalling probably has a central role in the
pathogenesis of androgen independent prostate cancer. Mutations in the androgen
receptor gene, in contrast to the oestrogen receptor gene in breast cancer, theoretically
should confer phenotypic changes more readily since the androgen receptor gene is x-
linked and, therefore, requires only one allele to be altered (Taplin et al 1995).
Androgen independence, in theory, may be mediated through mutations of the
androgen receptor gene that alter expression of androgen receptor or its ligand
sensitivity. Several groups have described various mutations in the steroid binding
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6domain of the androgen receptor in patients with androgen independent prostate
cancer (Taplin et al 1995, Elo et al 1995). Other investigators have found androgen
receptor missense mutations in tumours from patients with androgen independent
prostate cancer (Visakorpi et al 1995, Zhao et al 1999), although the frequency of
these mutations is debated. This variable mutation frequency may reflect, in part,
different patient populations, the methods used to detect mutations, or tumours from
primary versus metastatic sites. Most studies in patients treated with androgen
ablation monotherapy have found a low frequency of androgen receptor mutations.
Most mutations were found in patients treated with an androgen receptor antagonist
(flutamide) in conjunction with androgen ablation (Balk 2002). This finding suggests
that flutamide treatment is selecting for tumour cells with androgen receptor
mutations. The mutation found most frequently in the flutamide-treated patients
(codon 877 threonine to alanine) was identical to the mutation identified initially in
the LNCaP cell line (Veldscholte et aI1990).
In the early stages of prostate carcinogenesis, cells retain some degree of androgen
dependence and respond to androgen ablation therapy. Disease progression is
associated with mutations and produces clones of autonomous cells and autocrine
growth-promoting factors which are unresponsive to androgen withdrawal (Lee
1997). The proliferation of such clones may be promoted by the autocrine production
of transforming growth factor-alpha (TGF-a) through the epidermal growth factor
receptor (EGF-R). Enhanced growth factor production through oncogene activation,
dysfunctional growth factor receptor expression, and ultimate loss of growth
suppressors such as p53 and retinoblastoma (Rb) are probably responsible for the
androgen independent progression of prostatic cancer (Griffiths and Morton 1999).
The role of p53 in damage responses
Tumour suppressor genes playa fundamental role in cell division and growth control.
When these genes fail to function properly, deregulated growth -- a defining feature of
cancer cells -- ensues. The p53 tumour suppressor, first described in 1979 (Lane and
Crawford), has emerged as the most commonly altered gene and growth suppressing
pathway in human cancer.
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7The p53 tumour suppressor protein is often described as the "guardian of the genome"
because it is a critical component of the cell in its response to genotoxic stress ie.
DNA damage, hypoxia, etc. (Figure 1). P53 maintains genomic integrity in part by
arresting cell cycle progression or by inducing apoptosis (Levine 1997). Consistent
with this view, about 50% of primary human tumours carry mutations in the p53 gene
(Greenblatt et al 1994). The mechanism by which p53 is activated by cellular stress
has recently been shown to depend on ATM proteins which associate with p53 in the
absence of DNA damage. Following double-strand break formation, the complex
dissociates when they phosphorylate each other at serine position 1981 in the protein
(Bakkenist and Kastan 2003).
Wild-type p53 plays a role in the induction of G1 arrest, DNA repair and apoptosis
following DNA damage (Lee and Bernstein 1995). The p53-mediated G1 arrest
results from the transactivation of several cellular molecules, in particular p21 and
gadd45 (Hwang and Musehel 1998). P21 inhibits CDKlcyclin activity which
indirectly suppresses the expression of the transcription factor E2F, required for the
expression of S-phase-specific genes. This causes a G1 arrest (Gartel et aI1996). The
high levels of p21 and gadd45 increase repair mediated by proliferating cell nuclear
antigen (PCNA) and DNA excision (Prosperi 1997). The mdm2 gene is positively
regulated by p53, and inhibits p53 function (Wetzel and Berberich 1998). P53
activation also leads to the synthesis of cyclin G, which is thought to be involved in
G2 arrest (Shimitzu et al 1998). P53 induces apoptosis through pathways which are
not yet fully understood, but is thought to involve activation of the ICE proteases and
the bax gene which acts as a positive regulator (Enoch and Norbury 1995). Bcl-2
inhibits apoptosis (Hickman 1998).
Since the p53 protein is involved in all known damage responses and might also play
a role in G2 arrest (this is still not well-defined), the cellular p53 status plays a crucial
role in cell survival. The downstream effects of p53 have lead to contradictory
hypotheses regarding the influence of p53 status on radiosensitivity (Bristow et al
1996). For example, wild-type p53 could facilitate apoptosis leading to increased cell
death, but it could also induce a G1 and/or G2 arrest and increase DNA repair leading
to increased cell survival. Many contradictory reports have been published in this
regard (for review see Morgan and Kastan 1997) which may be explained by the fact
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8that p53-dependent apoptosis and G1 arrest followed by DNA repair and cellular
recovery appears to be controlled by different downstream pathways and that the
activity of these pathways is cell-type specific. The fact that a large number of
tumour types exhibit mutated p53 genes distinguishes them from normal cells. It may
be possible to exploit this to kill tumour cells. One example is the preferential chemo-
and radiosensitisation of p53 mutant tumour cell lines by radiosensitising agents
which abrogate the G2 cell cycle block (Binder et a12000, Serafin et aI2001).
I Cell type specific response
Cell growth arrest
Genotoxic stress
External and internal signals
l-- ONA repair
1- Apoptosis
ATM:DNA·PK
and other kinas"
Cell differentiation
--- .... ---cchanges in eenadhesion
«(kadherln$ and jntegrtm~)
Secretion of extracellular factors
(growth inhibitor.)
\...__. Apoptosis of target eeUs
Figure 1: p53 is activated by several types of stress and induces the expression of
several proteins that are involved in the inhibition of cell proliferation or in promoting
cell death by apoptosis. In tumour cells, the growth-arresting and apoptotic effects of
p53 might be lost owing to the mutation of genes downstream ofp53, to mutations in
the p53 gene, or to mutations or alterations in the levels of proteins that modulate the
p53 function.
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Apoptosis
Apoptosis is a central mechanism in tissue homeostasis ensuring that cell loss always
equals cell gain from mitosis. Disruption of the fine balance between cell
proliferation and cell death is thought to be an important step in the complex process
of carcinogenesis (Berges et aI1995).
Apoptosis has several distinct features which distinguish it from necrosis (Searle et al
1982). These are chromatin condensation, cell shrinkage, membrane blebbing and
DNA degradation at internucleosomallinkages (Wyllie et aI1981). This results in the
characteristic nucleosomal DNA repeat ladder evident in DNA electrophoretic gels.
Apoptotic cells are usually scattered throughout tissue rather than occurring in a large
block of contiguous cells as found in necrosis (Searle et al 1982). In contrast to
necrosis, inflammation is absent in apoptosis. Unlike necrosis, apoptosis arises from
activation of a specific genetic program. It has been described as "death from the
inside out". In the cell, apoptosis is initiated by a cascade of highly specialised
sequences of protein and DNA cleavage. Protein cleavage results from activation ofa
family of cysteine proteases or "caspases", while DNA is cleaved by endonucleases
(Peter and Krammer 1998). The activation of these processes can only start if the cell
has sensed damage and signalled this to the appropriate cell machinery. A number of
tumour suppressor genes such as p53, and oncogenes such as myc and bcl-2, have
been implicated in the recognition and signalling process (Konop leva et al 1999).
Intricate pathways leading to apoptotic death have been identified, eg. the eeramide
pathway (Venable et al 1995, Mizushima et al 1996), the stress-activated proteinljun
kinase (SAPKlJNK) cascade (Kasibhatla et al 1998), and the mitogen-activated
protein kinase/extracellular-signal regulated (MAPKlERK) pathway (Blagosklonny
1998). A simplified diagram describing the basic apoptotic pathways is given in
Figure 2.
Several other molecules like bcl-2, bax, and other pro- and anti-apoptotic molecules
determine the survival "threshold" of a certain cell type (Reed 1995) and have been
identified in androgen independent prostate cell lines and tissues. Androgen
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independent prostate cells maintain the ability to undergo apoptosis smee the
apoptotic program appears to be functional, if not intact and complete (Denmeade et
al 1996); thus, it appears that androgen withdrawal fails to initiate the apoptotic
pathway. Possible reasons for this failure could be the increased expression of genes
associated with enhanced cellular survival such as bcl-2, or pS3 mutations involved in
triggering apoptosis in response to injury or DNA damage (Colombel et al 1993).
The anti-apoptotic protein, bcl-2, seems to be important to the development of the
androgen resistant phenotype and to the resistance to chemotherapeutic agents (Raffo
et aI1997). This hypothesis has gained support from recent observations that PC-3, a
pS3 null, androgen independent human prostate cancer cell line, can be triggered to
undergo apoptosis upon treatment with several conventional chemotherapeutic drugs
including cisplatin, etoposide and vincristine, and camptothecin (Bomer et aI199S).
Normal human prostatic secretory cells do not express the bcl-2 protein. Hormone
refractory prostate cancer tissue derived from hormone-treated patients show a strong
bcl-2 expression suggesting that the increased expression of this protein provides
prostate cancer cells with the ability to survive outside of the hormonal milieu
(Berchem et aI199S). Interestingly, androgens have been shown to induce expression
of bcl-2 protein in hormone sensitive LNCaP cells, which may represent one of the
mechanisms whereby hormone dependent prostatic cancer cells evolve into androgen
independent cells.
On the other hand, downregulation of bcl-2 expression with gene-specific antisense
oligos has been shown to abolish the bcl-2-conferred resistance to apoptosis induction
(Berchem et aI199S).
The pS3 tumour suppressor gene is the most frequently mutated gene found in
multiple human malignant tumours, including prostate cancers. Several studies have
shown pS3 mutations to be relatively rare in prostate cancer, in general, but to be
much more frequent in advanced tumours. Mutations of the naturally present wild-
type pS3 permit cells with altered genomic composition to maintain proliferation
which in tum can result in the acquisition of additional genetic abnormalities (Sakr
and Grignon 1997).
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Whether p53 is a requirement of prostate cancer cells to undergo apoptosis is still
unclear. The fact that androgen ablation-induced apoptosis does not appear to involve
p53 and that multiple chemical entities induce apoptotic death of p53 null PC-3 cells
(Bomer et al 1995) suggests that p53 may not be essential for the apoptotic response
to occur in these situations (Berges et aI1993). However, since p53 has an important
role in introducing the Ga/Gl checkpoint, attenuation or loss ofp53 activity after DNA
damage could represent an early event in prostate oncogenesis, leading to an increased
probability of a cell accumulating the genetic alterations necessary for transformation.
It is widely suggested that apoptotic propensity could be an indicator for sensitivity to
irradiation and drugs. Apoptotic propensity, therefore, is of considerable importance.
While some cells exhibit a high apoptotic propensity within hours after irradiation or
drug treatment (Mirkovic et al 1994, Weil et al 1996), others express significant
levels of apoptosis only after days (Guo et al 1999). Some cells show little, if any,
apoptosis and enter other death pathways. High apoptotic propensity also may reflect
high sensitivity to cytotoxic treatment, but a low apoptotic propensity does not
necessarily imply high resistance to cytotoxins (Olive et al 1996). In most tumour
cells, mitotic cell death is at least as important as apoptosis, and in some cases it is the
only mode of cell death.
Stellenbosch University http://scholar.sun.ac.za
12
TNF-related apoptosis inducing ligand
Ionising radiation
(Induce DNA strand breaks)
Chemotherapeutic drugs
camptothecin
gene expression
Pro-apoptotic genes:
e.g. bax, p53, c-jun
Figure 2: Basic apoptotic pathways. There are two main routes to cell death, one
involving stimulation of death receptors by external ligands, and one arising within
the cell and involving the mitochondria. The death receptor pathway is activated
when members of the tumour necrosis factor (TNF) family of ligands bind to the
receptors. This recruits adapter proteins that activate initiator caspases (eg. caspase
8), which in tum activate effector caspases, such as caspase 3. The mitochondrial
pathway is activated by diverse signals, one being DNA damage. DNA damage
which cannot be repaired, induces pS3 protein which activates a sub-pathway that
results in release of cytochrome C from the mitochondria, with subsequent
involvement of the apoptosome and activation of the initiator, caspase 9. Both these
pathways converge on the effector, caspase 3, to initiate proteolysis and activation of
nucleases to effect cell kill. The survival factor sub-pathway normally holds
apoptosis at bay by inhibiting the mitochondrial pathway through activation of
members of the anti-apoptotic bcl-2 family.
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DNA Repair
Ionising radiation induces various types of DNA damage, including double-strand
breaks, single-strand breaks, base damage and DNA-protein erosslinks (Arrand and
Michael 1992). DNA double-strand break induction and repair, and the fidelity of
repair, seem to be critical factors which determine radiosensitivity in human cell lines
(Nunez et al 1996). Since chemotherapeutic agents such as alkylating agents,
inhibitors of DNA topoisomerase II, and inhibitors of topoisomerase I and
antimetabolites are known to induce double-strand breaks, issues relating to double-
strand break repair is important for the clinical oncologist.
Human cells repair DNA double-strand breaks by either of two repair pathways: the
non-homologous end-joining (NHEJ) pathway, and the homologous recombination
(HR) pathway (Figure 3) (Karran 2000, Thompson and Schild 2001). Homologous
recombination repairs double-strand breaks using the sister chromatid as a template,
removing damage in an error-free process (Liefshitz et al 1998). By contrast, non-
homologous end-joining does not require homology to couple the DNA fragments in
double-strand breaks. Because NHEJ simply attaches ends together and does not use
a template, it is more error prone and more likely to result in chromosomal damage.
Because HR requires a template, this mechanism is most efficient in the late Sand G2
phases of the cell cycle, when a sister chromatid is available as a template. Acting in
coordination with the Sand G2 checkpoint controls, HR helps to eliminate
chromosomal damage before cell division occurs. By contrast, NHEJ is more likely
to be the repair mechanism used during G1 (or Go) and on unreplicated DNA in S
phase. Accumulating evidence (Takata et al 1998, Essers et al 2000), indicates that
the relative contribution of HR and NHEJ varies, depending on the cell lines used and
the phase of the cell cycle, and that HR is more important in mammalian cells than
previously thought (Sonoda et a11999, Moynahan et aI1999).
Enzymes which are activated by DNA strand-breaks, eg. poly-ADP-ribose-
polymerase (PARP) and mdm2 have been implicated in the sensing of DNA damage
(Momand and Zambetti 1997). PARP is thought to indirectly activate pS3, p21 and
DNA-PK (Le Ruhn et a11998).
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A variety of assays exist for determining the level of DNA and chromosomal damage,
and the subsequent repair. The unifying feature of these techniques is that they
quantify damaged and undamaged DNA. This is then used as an indirect signal for
predicting survival. A cell's ability to retain reproductive integrity is not only related
to the level of damage inflicted, but is also an expression of damage repair (Roos et al
2000). The major limitation of repair assays is the distribution of cells in cell cycle
phases. Variations in cell distribution can produce significant variations in expression
of damage and, therefore, render the prediction of survival unreliable in relation to the
amount of residual damage (Wlodek and Hittelman 1988). Several investigators
(Andrews 1994, Perego et al 1998, Wang et al 2001) have shown that resistance to
chemotherapy agents is often mediated by enhanced DNA repair, enhanced drug
metabolism, or reduced drug accumulation, mechanisms that all precede the
"apoptotic decision point".
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Figure 3: Schematic diagram of two important DNA repair pathways. In the non-
homologous end-joining (NHEJ) pathway, the termini of a DNA double-strand break
induced by ionising radiation are bound by the Ku70/80 / DNA-dependent protein
kinase catalytic sub-unit complex, or by Rad52. Rejoining of the DNA ends, by
filling in new nucleotides in the absence of any homology, is facilitated by DNA
ligase IV and Xrcc4. DNA repair by homologous recombination (HR) occurs in Gz
after replication and involves strand invasion of the intact sister chromatid, facilitated
by Rad51, using the undamaged DNA as a template.
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The significance of the repair and apoptotic pathway as indicators of drug toxicity and
successful cell inactivation is not clear at present. It is entirely possible that other cell
death pathways are operating and that apoptotic propensity may not be strictly
diagnostic of drug effectiveness. The role of repair in drug effectiveness is also
obscure. It is anticipated that the present research will shed light on this question.
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Thesis objective
The literature overview in the preceding introduction demonstrates that the treatment
of prostate cancer remains difficult. The poor response of prostate cancer to
chemotherapeutic drugs and to irradiation could be due to: inter-patient variation,
inherent drug- and radioresistance, and effective DNA damage repair. The cell
biological approach chosen here assesses basic damage responses, such as apoptotic
propensity, checkpoint activation, p53, and repair capacity, in cell lines of defined p53
status.
The "classic" prostate cell lines, DUI45, PC-3 and LNCaP, have contributed to the
present understanding of prostate cancer. However, their relevance to the problem is
limited because they derive from metastatic, and not from primary normal and tumour
epithelium. Cell lines derived from primary benign and malignant human tumour
prostate epithelium are now available (Hayward et a1I995, Bright et aII997). These
new cell lines (1532T, 1535T, 1542T, 1542N, and BPH-l) express functional
characteristics of prostatic epithelial cells and provide a new opportunity to examine
the role of basic cell damage responses (repair, checkpoint activation, apoptosis and
associated signalling proteins, and the influence of androgen status) in cell
inactivation, and their relevance in treatment. Particular importance thus is attached
to the use of a more realistic cell biological model. The results from this investigation
thus could provide a new basis for the understanding of irradiation and drug resistance
in prostate tumours.
I have assessed the following aspects
(1) The influence of p53 status, p53 functionality and androgen dependence on cell
survival in response to anticancer drugs in 1532T, 1535T, 1542T, 1542N, BPH-l and
LNCaP prostate cell lines.
(2) The role of p53 and bax/bcl-2 on apoptotic propensity induced by irradiation and
anticancer drugs.
(3) The influence of DNA repair on damage response and survival.
(4) The role ofapoptosis as a diagnostic parameter in drug effectiveness.
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CHAPTER2
MATERIALS AND METHODS
Cell lines
BPH-l
The epithelial cell line, BPH-1 (benign prostatic hyperplasia-I), was established from
human prostate tissue obtained by transurethral resection. Primary cell cultures were
immortalised with simian virus 40 (SV40) large T-antigen (Hayward et al 1995).
BPH-1 has a cobblestone appearance in monolayer culture and grows in RPMI 1640
medium supplemented with 10% heat-inactivated foetal bovine serum (FBS),
penicillin (WOU/ml) and streptomycin (LOuug/rnl) (Highveld Biological, South
Africa). The cells were obtained from Professor SW Hayward (Department of
Urology, University of California).
1535-CP1 TX, 1532-CP2 TX, 1542-CP3 TX and 1542-NPTX
The malignant (CPI, CP2, CP3) and benign (NP) prostate epithelial cell cultures were
derived from primary adenocarcinomas of the prostate resected from 6 patients. The
cells were immortalised with the E6 and E7 transforming proteins of the human
papilloma virus serotype 16 (HPV-16) (Bright et al 1997). The growth medium
consisted of WAlC 404 Medium (Gibco BRL, Scotland) containing HEPES, sodium
hydrogen carbonate, zinc stabilised insulin, cholera toxin, dexamethazone, epidermal
growth factor (Sigma, Germany), penicillin (1OOU/ml), streptomycin (1Ouug/ml) and
0.5% heat-inactivated foetal bovine serum (Highveld Biological), as described by
Bayne and colleagues (Bayne et al 1998). The growth medium used by the
originators of the paired prostatic cell lines, 1535N, 1535T, 1532N, 1532T, 1542N
and 1542T, was keratinocyte serum-free medium (Keratinocyte SFM) containing
bovine pituitary extract, epidermal growth factor, L-glutamine, HEPES buffer,
antibiotics, and heat-inactivated foetal bovine serum (Bright et al 1997). For
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economic reasons, WAJC 404 medium was used. In non-optimised conditions, the
culture may select for cells which survive better under different circumstances. In
addition, cell populations which grow in vitro for a number of generations are prone
to genetic and phenotypic changes, which may be an expression of their need to adjust
to a new environment. Cell growth rates, too, may differ from medium to medium.
The hallmark of an adequate culture medium is that it supports high levels of cell
viability. In this regard, the clonogenic assay sets the most exacting standard for the
adequacy of a medium. The cells were provided by Professor JRW Masters (Prostate
Research Centre, University College London) and Professor JA Macoska (Department
of Urology, University of Michigan Comprehensive Cancer Center).
LNCaP.FGC
The LNCaP cell line was established from a supraclavicular lymph node metastasis of
human prostatic adenocarcinoma (Horoszewicz et al 1983). LNCaP has a
fibroblastoid morphology, low anchorage potential, is adherent but grows in
aggregates and as single cells in RPM! 1640 medium supplemented with 5% heat-
inactivated FBS, penicillin (IOOU/ml) and streptomycin (IOOIJ.g!ml) (Highveld
Biological). The cultures require gentle handling at all times because the cells are
easily dislodged by tapping, shaking or pipetting. The low anchorage potential is also
responsible for the 10-20% cell loss during media changes in long-term experiments
(Horoszewicz et ai, 1983). The cells were obtained from Professor Helmut Kloeker
(Department of Urology, University oflnnsbruck).
RT4
The RT4 cell line, derived from a transitional-cell bladder carcinoma (Chresta et ai,
1996), is adherent and grows as a monolayer in RPM! 1640 medium supplemented
with 10% heat-inactivated FBS, penicillin (IOOU/ml), streptomycin (1001J.g!ml), and
2mM glutamine (Highveld Biological). The cells were obtained from Professor JRW
Masters (Prostate Research Centre, University College London).
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Cell culture maintenance
Cells were maintained at 37°C and 5% CO2 in Forma Scientific incubators and all
procedures were carried out in laminar flow hoods using aseptic techniques. In all
cases, LNCaP cells, once seeded, were left for at least two days, as described in
Horoszewicz et al (1983), to attach to the surface of the cell culture flasks before
experiments were conducted.
Cytotoxic Drugs
Vinblastine Through its binding to tubulin, this vinca alkaloid, C46H58N409,inhibits
the assembly process of microtubuies leading to dissolution of the mitotic spindle.
Vinblastine (VINBLASTINE PCH, Pharmachemie Ltd) is a cell cycle-specific agent
and blocks mitosis with metaphase arrest. Each vial contains 1mg/ml of Vinblastine
sulphate. Vinblastine has a molecular weight of 811.00
Estramustine A stable conjugate of estradiol and nor-nitrogen mustard, estramustine
(ESTRACYT 3, Pharmacia and Upjohn), in addition to inhibiting assembly of the
nuclear matrix, depolymerizes microtubules by binding to tubulin- and microtubule-
associated proteins, and inhibits the multidrug resistance transporter, P-glycoprotein.
Estramustine, C23H31CL2N03,has a molecular weight of 440.41 and is prepared as a
sterile stock solution of 10mg/ml in dimethyl sulphoxide (DMSO).
Etoposide The predominant macromolecular effect of this topoisomerase II inhibitor,
C29H32013, (EPOSIN IV, Pharmachemie (Pty) Ltd.) appears to be the induction of
DNA strand-breaks by an interaction with DNA topoisomerase II. Etoposide was
supplied as a stable solution (20mg/ml concentrate for infusion) and remained stable
when added to aqueous media. Etoposide has a molecular weight of 588.58
Estramustine and Etoposide were stored at room temperature (22°C), Vinblastine at
4°C. Fresh stock solutions were used for each experiment. The criterion for drug
selection was clinical potential and suitability for use in cell culture without
microsomal activators.
Stellenbosch University http://scholar.sun.ac.za
21
Mycoplasma testing
Cell cultures were tested for mycoplasma contamination. Single-prostate-cell
suspensions (2x 104 cells) were seeded in 35mm plastic petri dishes (Coming, New
York) containing 22mm glass coverslips (Chance Propper, England) to a final
medium volume of 2ml, and allowed to grow for 3-5 days. The medium was then
removed and the cells fixed in methanol:glacial acetic acid (3: 1, v/v) for 5 minutes.
The coverslips were air-dried and submerged for 1 minute in Hoechst 33258 stain
(Sigma, Germany) at a concentration of 0.51lg/ml in Hanks balanced salt solution.
The coverslips were then washed three times in phosphate buffered saline (PBS)
before being mounted, using citric acid-disodium phosphate buffer (pH5.5), on glass
microscope slides and observed under the fluorescent microscope. Mycoplasma
contamination can be identified by the presence of speckled perinuclear fluorescence
(Chen et al 1977). All cell lines used were found to be free of mycoplasma
contamination.
Growth curves and cell doubling times
Exponentially growing cells were trypsinised, counted and seeded at 5 x 104 cells/ml
into 25cm2 flasks. Flasks were set up in triplicate per time point and cell numbers
determined over a period of 120 hours. For counting, the cells were harvested by
trypsinisation, resuspended in medium, and a known dilution in Isoton II counted with
a Coulter Cell Counter (Coulter Electronics, USA). The means of the triplicate counts
were plotted against time on a log scale.
Doubling time (DT) was calculated as follows:
DT = 102 = 0.693
b b
where b = the slope of the linear regression between cell number, on a log scale, and
time, on a linear scale.
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Irradiation procedure
The 60Co y-irradiation source at Tygerberg Hospital was used. Dosimetry was by
Thermo Luminescent Dosimetry (TLD-chips). The beam configuration was vertical
with a source-to-sample distance (SSD) of 80cm measured to the base of the
experimental flasks. The field size was 30 x 30cm2. Build-up consisted of 10mlof
medium in the 25cm2 culture flasks and a 5mm perspex sheet positioned on top of the
culture flasks. The backscatter was absorbed by a 5cm thick perspex sheet.
For the clonogenic assay cell cultures were irradiated at room temperature (22°C)
over a dose range of O-lOGy at a dose rate of l.OGy/min. For the DNA repair
experiments, the prepared gel plugs (BioRad, USA) containing cells were irradiated
on ice over a dose range of 0-1OOGyat a dose rate of approximately 2.92Gy/min. The
SSD for this set-up was approximately 6cm and the field size was 30 x 35cm2.
Flow cytometric determination of G2 block expression
To establish the time of maximum G2IM phase arrest, exponentially growing cells in
25cm2 tissue culture flasks were exposed to a single 60Co y-irradiation dose of 7Gy.
This was followed by harvesting cells at 2-hourly time intervals for up to 40 hours by
trypsinisation, centrifugation and fixation in 70% ethanol at -20°C. The DNA content
of the cells was measured to determine the time of maximum G2 block expression
(Ormerod 1999). Briefly, cells were stained in PBS containing 1Oug/rnl propidium
iodide (PI) solution (Sigma, Germany) and l Ouug/ml RNase (Sigma, Germany) at
37°C for 30 minutes. Analysis was done on a FACScan (Becton Dickinson, USA)
flow cytometer at 488nm. Red fluorescence (PI) was collected as a linear signal and
recorded as a measure of the total DNA content. Cell doublets were gated out by
processing red fluorescence into area and width. Estimates of cells in the different
cell cycle stages, obtained by placing markers on DNA histograms, revealed the time
of maximum G2 block expression.
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Clonogenic survival assay
Near-confluent stock cultures were washed with sterile PBS, trypsinised and counted
using a haemocytometer. Cells were seeded in triplicate per experiment in 25cm2
culture flasks at numbers to yield 100-200 colonies per flask and allowed to settle for
a minimum of 6 hours. Irradiation response curves were obtained by exposing cells to
graded doses ranging from 0-1OGy. After an appropriate time of incubation (10-12
days) the colonies were fixed, stained and scored. Cell survival curves were fitted to
the linear-quadratic survival equation:
. - (aD + /11)2)Survivali S'ï = e
where S is the survival ratio, a and p are inactivation constants, and D is the dose in
Gy. Mean surviving fractions from three independent experiments were plotted on a
linear-linear scale, and the mean inactivation dose, D, was used as the measure of
radioresistance (Fertil et aI1984).
D, was obtained by the numerical integration of the linear quadratic function, as
follows:
oe
D= fS(D)dB
o
where SeD) is the dose dependence of the surviving fraction or the probability that a
dose larger than D is necessary to inactivate a cell which has been randomly selected
from the population (Fertil et al 1984). D is equal to the area under the survival
curve. Within the concept of D, the survival curve is treated as a probability
distribution of dose (Fertil et al 1984).
D has been shown to be suitable for modelling mammalian cell survival curves
(Deschavanne and Fertil 1996). The use of D is advantageous for several reasons: D is
model-free and, as the radiosensitivity is evaluated by a single parameter, its statistical
handling is simplified. All the experimental data are used with the same statistical weight
and D minimises experimental fluctuations.
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Proliferation arrest of prostatic cells by Sa-DHT
10000 cells were seeded in 24-well multiwell plates with medium containing
charcoal-stripped (es) FBS. The medium for the I532-CP2TX, 1535-CPITX, 1542-
CP3TX and 1542-NPTX cell lines was supplemented with 0.5% csFBS, the BPH-I
cell line with 10% csFBS, and 5% csFBS for the LNCaP cell line, which served as the
positive control. 5a-dihydrotestosterone (DHT) was added a day later (2 days later in
the case of LNCaP) in concentrations ranging from C.OOI- 10nM, for a period of 4
days. The experiment was stopped after 4 days and the cell growth determined by
crystal violet assay, as described by Baker and colleagues (1986). Two control flasks
were set up, one with charcoal-stripped FBS and one with "normal" FBS. The optical
density (OD) readings, expressed as a percentage of the control OD, were plotted
against concentrations ofDHT.
Drug Toxicity
Drug concentrations for the vanous cell lines were determined as follows.
Exponentially growing cells were trypsinised, counted and 10000 cells/ml seeded into
24-well multi well plates. The cells were allowed to settle for 6 hours before the
addition of varying concentrations of drug. Working solutions of the various drugs
were freshly prepared for each experiment. After 24 hours of drug exposure, the
medium was changed and the multi well plates re-incubated for a further 4 days. The
cells were then fixed with a solution of buffered formalin (pH 7.2) and stained with
0.01% crystal violet. The crystal violet stain was dissolved in lrnl of a 10% sodium
dodecyl sulphate (SDS) solution overnight and the optical density of the extracted
stain read on a Perkin-Elmer Lambda 5 spectrophotometer at 590nm. Cell survival at
each drug concentration was expressed as a percentage of the control survival rate, ie.
where no drug was present in the growth medium, corrected for cell plating
efficiency.
Immunochemical detection of p21WAFl
p21WAF I detection was performed according to a modification of the protocol of
Deptala and colleagues (Deptala et al 1999). Cells were fixed in I% methanol-free
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Immunochemical detection of p21WAFt
p21WAF!detection was performed according to a modification of the protocol of
Deptala and colleagues (Deptala et al 1999). Cells were fixed in 1% methanol-free
formaldehyde in PBS at 4°C for 15 minutes, washed with PBS, and permeabilised
with 80% ethanol at -20°e. After fixation and re-swelling in PBS at room
temperature (22°C) cells were lysed in 0.25% Triton X-IOO on ice for 5 minutes.
Cells were then washed with PBS containing 1% bovine serum albumin (BSA) and
incubated overnight at 4°C with 1O01l1of 1% BSA/PBS containing lug of anti-
p21WAF!antibody (clone 2G12; PharMingen, USA), or 3111of mouse anti-IgGl (Dako,
Denmark) in a 1:30 titre as a negative isotype control. The cells were then washed in
1% BSA/PBS and incubated in IOOll1of 1% BSA/PBS containing 31lg of mouse anti-
IgGl secondary antibody (Sigma, Germany) for 1 hour in the dark at room
temperature. Induction of p21WAF!was visualised in dot plots of red fluorescence (PI)
against green fluorescence (FITC) by flow cytometry. The p21-labelled cells were
identified by their green fluorescence and were above the Gi-phase population. The
G!- and the Gs-phase populations were clearly identified by their lack of p21 antibody
reactivity. Cell Quest software was used for the analysis. The p53 wild-type cell line,
LNCaP, served as the positive control.
DNA repair (CFGE) assay
The amount of DNA double-strand break damage was determined by constant-field
gel electrophoresis (CFGE), as previously described (Wlodek et al 1991). Confluent
cultures were used to avoid S-phase variations between cell lines (Dikomey et al
1998). Cells were encapsulated in agarose during irradiation and repair. This
procedure was optimised according to Kysela and colleagues (1993) in order to
minimise non-specific DNA damage. Briefly, 1532T, 1535T, 1542T, 1542N, BPH-I
and LNCaP cells were harvested by trypsinisation and re-suspended in a 0.5% low
melting point agarose solution. Aliquots of 30IlI, containing ~ 1 x 105 cells were
placed into each well of a disposable plug mold (BioRad, USA), and allowed to
solidify at 4°C for 45 minutes. Plugs were irradiated in ice-cold DMEM containing
2% HEPES and 7.5% (w/v) NaRC03, over a dose range of 0-100Gy 60Co y-
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irradiation, on ice. Samples for the determination of initial damage were immediately
submitted to lysing and washing steps. The residual damage was determined by
incubating the plugs at 37°e in growth medium for periods of 2 hours and 20 hours
prior to lysing and washing.
For both protocols (initial and residual damage), plugs were submersed in an ice-cold
Iysing solution containing SOmM ethylene diamine tetra-acetic acid (EDT A), 1%
sodium dodecyl sulphate and Irng/ml proteinase K. Incubation for 1 hour at 4°e was
followed by lysing at 37°e for 20 hours. Agarose plugs were then washed five times
and stored in 2ml of SOrnMEDTA solution.
The washed agarose plugs were then loaded onto a 20 x 20cm 0.6% agarose gel and
run in 0.5 x TBE buffer for 24 hours at a constant field strength of 1.2V/cm. Gels
were stained with ethidium bromide (O.S~glml in 0.5 x TBE) and subjected to
fluorometric analysis with aGeneSnap (VacuTec) image analysis system. Three
independent experiments were performed for each cell line. The fraction of DNA
released from the plug was obtained from the following equation: Frei= flrelI (flplug+
flrel), where flrel and flplugcorrespond to fluorescence measured in the lane (DNA
released) and in the plug, respectively. Untreated control samples were used for each
sample sub-set to subtract background fluorescence caused by non-specific DNA
degradation.
Dose-response curves were obtained by plotting dose (Gy) vs. the fraction of DNA
released (Frei) as calculated above, representing initial damage (0 hours), residual
damage (2 hours) and residual damage (20 hours). Since data could not be fitted by
linear regression, data points were connected and the area under the curve (AUe) was
calculated for each curve using GraphPad Prism (GraphPad software, USA). DNA
double-strand break (dsb) rejoining capacity after 2 hours or 20 hours incubation was
then determined as the ratio AUeol AUe2 or AUeol AUe2o, where AUeo is the area
under the curve at 0 hours.
Measurement of in vitro apoptosis
The apoptosis assay was performed, as described previously (Akudugu and Bohm
2000). Single-prostate-cell suspensions (2xl04 cells) were plated into 3Smm plastic
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petri dishes (Coming, New York) containing 22mm glass coverslips (Chance Propper,
England) to a final medium volume of 2mI. The cells were rendered apoptotic by
exposure to TDso concentrations of Etoposide, Vinblastine and Estramustine. Treated
and untreated cultures were fixed in methanol:acetic acid (3:1, v/v) at intervals
between 0 and 48 hours, air-dried, stained with acridine orange, and the coverslips
mounted on glass microscope slides for fluorescent microscopy. Adherent cells were
harvested and combined with cells floating in the growth medium. A preliminary set
of experiments was performed to establish the time at which each cell line, exposed to
a TDso concentration of drug, had expressed maximum apoptosis.
A minimum of 500 cells was evaluated per sample for each time point and the
frequency of apoptotic cells, corrected for spontaneous apoptosis in untreated
samples, was scored according to criteria described elsewhere (Mirkovic et al 1994,
Weil et al 1996). These included cells with either pyknotic, fragmented or crescent-
shaped nuclei, overall shrinkage, or membrane-bound bodies containing pyknotic
nuclei that were smaller than the normal surrounding nuclei. Three independent
experiments were subsequently performed for each cell line and drug, and the
frequency of apoptotic events expressed as the mean (±SD) ratio of apoptotic cells to
the total number of cells scored.
Acridine orange staining to identify morphological features of apoptosis
The DNA dye, acridine orange (Sigma, Germany), was used to identify the
characteristic chromatin changes associated with apoptosis. Acridine orange is
retained in cells that have an intact cell membrane, which includes the majority of
apoptotic cells, but excludes necrotic cells or very late stage apoptotic cells (Figure 4).
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Figure 4: Apoptotic and non-apoptotic cells of the 1542T prostate line, following
exposure to a TD50 concentration of the apoptosis-inducing drug, etoposide.
BcI-2 and Bax analysis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used
to determine changes in the expression of bax and bcl-2 proteins. This method
separates proteins by the relative distance they migrate through a polyacrylamide gel
matrix, based on their molecular weights.
Sample preparation
Apoptotic cells detached from the monolayer after drug treatment were collected by
centrifugation and combined with the monolayer cells that had been detached by
gentle scraping. The cells (2 x 106) were washed in ice-cold PBS, resuspended in
200111of PBS containing protease inhibitors, phenylmethylsulfonylfluoride (LOul/rnl;
Sigma, Germany) and aprotinin (30Ill/ml; Sigma, Germany), and sonicated (Branson,
USA) for 10 seconds at an amplitude of 271lm. Protein concentration was determined
by Bradford dye binding assay, and 251lg of protein was used per sample.
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Preparation of aery lam ide gels
A Hoefer SE200 (Hoefer Scientific Instruments, USA) mighty small vertical slab gel
electrophoresis unit was used. A 12% separating gel, with a 4.5% stacking gel, was
used for optimum resolution of the bax and bcl-2 proteins. Briefly, the separating gel
was prepared by mixing appropriate volumes of the following solutions: 4ml of
bisacrylamide (37.5: 1% w/v), 2.5ml ofTris l.5M (pH 8.8), 3.35ml of distilled water,
and O.lml of 10% SDS. After degassing the mixture, 50111of freshly prepared 10%
ammonium persulphate and l Oul of TEMED were added to initiate the reaction. The
stacking gel was prepared as follows: 975111ofbisacrylamide (37.5 : 1% w/v), 6251.rl
of Tris l.OM (pH 6.8), 50111of 10% SDS, and 3.375ml of distilled water. After
degassing the mixture, 25111of freshly prepared 10% ammonium persulphate and 10111
of TEMED were added to initiate the reaction. The tank buffer was prepared as
follows: 3.03gm Trizma base, 14.4gm glycine, and lOmlof 10% SDS were dissolved
in 1 litre of distilled water. The final pH was 8.4 - 8.6
Samples were boiled for 5 minutes in SDS sample buffer before loading onto the gel.
In addition, IOul of a precision pre-stained molecular weight marker (10-250kD;
BioRad, USA) was also loaded. Gels were run for approximately 50 minutes at 200V
until the dye-front reached the end of the gel.
Western transfer and immunoblot
Proteins were transferred onto a polyvinylidine difluoride (PVDF) membrane
(BioRad, USA). This microporous membrane has a high protein binding capacity
without degradation of the protein during elution and also has a high mechanical
strength. The membrane was pre-soaked in methanol for 30 seconds and then rinsed
in transfer buffer to remove the methanol (the PVDF membrane is extremely
hydrophobic and will not wet in aqueous solutions unless pre-wet with methanol).
The proteins were transferred from the gel to the membrane by electroblotting in
transfer buffer containing: glycine (192mM), Tris-HCl (lOmM) and methanol (20%),
at 200mA for llh hours at room temperature. Ponceau Red (Sigma, Germany)
staining of the PVDF membrane confirmed even loading of samples. The membrane
was then blocked in Tris buffered saline-Tween 20 (TBST) containing 10% non-fat
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milk powder, for 2 hours at room temperature. Five washes in Tris buffered saline
(TBS)rrween 20 solution followed, before the primary antibody was added and the
membrane left rotating overnight at 4°C. Incubation in the primary antibodies [mouse
anti-human bcl-2 (Ab-124) monoclonal antibody (DAKO, Denmark) and mouse
IgG2B bax (B-9) monoclonal antibody (Santa Cruz Biotechnology, Germany)] was
followed by several washes in TBS/Tween 20 solution, before the addition of the anti-
mouse IgG horse radish peroxidase antibody (Amersham, England) and incubation for
1 hour at room temperature. The membrane was then washed several times in
TBS/Tween 20 solution, before protein detection.
The EeL Western blotting detection system
Proteins were detected usmg the enhanced chemiluminescence (ECL) detection
system (Amersham). This is a rapid, highly sensitive, non-radioactive method for the
detection of immobilised proteins. In the ECL reaction the substrate, luminol, is
oxidised by a horse radish peroxidase-catalysed reaction resulting in blue light
emission. This can be detected using blue light sensitive film.
After 60 seconds incubation with the ECL detection reagents, the membrane was
removed from the liquid, cling-wrapped and exposed to Hyperfilm ECL (Amersham).
Exposure times varied from 1 minute to 30 minutes.
Ponceau S staining of PVDF membranes
PVDF membranes were stained with Ponceau S (Sigma, Germany) to expose the
protein bands and allow for an assessment of sample loading. Following protein
transfer by electroblotting, membranes were soaked in Ponceau S for 60 seconds and
rinsed in distilled water, before blocking with TBST containing 10% non-fat milk
powder.
Stripping and re-probing Western blots
The ECL detection system allows membranes to be stripped and re-probed with a
different antibody so that the same samples can be analysed for the expression of two
independent proteins.
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The membranes were submerged in stripping buffer containing 100mM p-
mercaptoethanol, 2% (w/v) SDS and 62.5mM Tris-HCI (pH 6.7), and incubated, with
occasional agitation, at 60°C for 30 minutes before being washed in TBST at room
temperature for 20 minutes. Blocking for 1 hour at room temperature in milk block
buffer followed before re-probing with primary and secondary antibodies, as
described previously.
Data evaluation
Data are presented as the mean ± standard deviation of three independent experiments
as indicated by error bars (Figures), and each experiment was repeated at least three
times. Statistical analysis and data fitting were performed by means of GraphPad
Prism (GraphPad Software, San Diego, USA). A two-sided t test was used to
compare the means between sample groups.
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CHAPTER3
RESULTS
Growth characteristics
The doubling times for the malignant cell lines, 1532T, 1535T and 1542T, were found
to be in the range of 28-29 hours. As expected, the normal cell line, 1542N, has a
longer doubling time (36 hours), whereas the benign BPH-1 cell line has a very short
doubling time (16 hours). The metastatic wild-type cell line, LNCaP, has a doubling
time of 45 hours.
Cell cycle changes after irradiation:
When cells are exposed to ionising radiation, the cell cycle is blocked at the GdS and
Gz/M transitions depending upon the p53 status of the cells.
In the 1532T, 1535T, 1542T, 1542N, and BPH-1 cells, which are p53 defective,
irradiation instead generates a block at the GzIM transition. As expected, the p53
wild-type cell line, LNCaP, showed a very pronounced delay at the GdS transition
and a smaller Gz/M phase delay.
In the p53-defective cell lines, 1532T, 1535T, 1542T, 1542N, and BPH-1, the Gz/M
delay was maximally expressed at 32, 24, 30, 36 and 14 hours, respectively, after
irradiation.
In the p53 wild-type cell line, LNCaP, the G1 and Gz blocks maxima occurred after 40
hours.
Radiosensitivity
The cellular radiosensitivity expressed in terms of the surviving fraction at 2Gy (SF2)
was determined by clonogenic assay. Cell survival data for the 6 human prostate cell
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lines were fitted to the linear-quadratic model and are presented in Figure 5. The SF2
values varied from 0.28 to 0.54. The cell inactivation parameters are summarised in
Table 1. The LNCaP and 1542T cell lines are the most radiosensitive, with SF2
values of 0.28 and 0.30, respectively. The 1532T and BPH-l cell lines are the most
radioresistant, with SF2 values of 0.52 and 0.54, respectively, while the 1542N and
1535T cell lines assume intermediate positions with SF2 values of 0.37 and 0.44,
respectively.
Cellular radiosensitivity expressed as the mean inactivation dose, D, is defined as the
area under the survival curve when plotted on a linear-linear scale (Figure 6) (Fertil et
al 1984). D-values for the irradiated panel of cell lines are shown to vary from 1.62-
2.77Gy (Table 1).
Table 1: Summary of cell inactivation parameters for 6 prostate cell lines determined
by clonogenic assay after exposure to 60COy-irradiation.
Cell line a (Gfl) P (Gf2) D(Gy) SF2
BPH-1 0.266 0.021 2.77 0.54
1532T 0.292 0.017 2.72 0.52
1535T 0.358 0.027 2.40 0.44
1542N 0.502 0.007 2.28 0.37
1542T 0.642 0.014 1.84 0.30
LNCaP 0.632 0.004 1.62 0.28
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Figure 5: Clonogenic survival curves for 6 prostate cell lines after 60COy-irradiatiou.
Symbols represent the mean (± Sn) surviving fraction from 3 separate experiments.
Survival curves were obtained by fitting experimental data to the linear-quadratic
model.
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Figure 6: Survival curves plotted on a linear-linear scale for 6 prostate cell lines after
60CO y-irradiation. Symbols represent the mean (± SD) surviving fraction from 3
separate experiments. Radiosensitivity was expressed in terms of mean inactivation
dose, (D), which is defined as the area under the survival curve of each cell line.
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Androgen sensitivity
The crystal violet vital dye staining assay shows that addition of 5a-
dihydrotestosterone (DHT) has no significant effect on cell growth in the 1532T,
1535T, 1542T, 1542N and BPH-I cell lines (Figure 7). In these cell lines growth in
charcoal-stripped foetal bovine serum (csFBS) equalled or exceeded growth in the
presence of O.OOI-IOnM DHT, indicating that they are androgen independent.
However, when the LNCaP cells were subjected to charcoal-stripped medium and
DHT was then added at concentrations of 0.001-1.0nM, growth was restored from
50% in csFBS to a level of 80% of control (FBS) (Figure 7). This confirms that
LNCaP cells are androgen sensitive. The fact that DHT did not restore growth to
100% indicates that factors, other than steroids, removed by charcoal treatment, were
essential for optimal growth.
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Figure 7: The effect of DHT addition (nM) to charcoal-stripped medium on the
proliferation of 6 prostate cancer cell lines, measured by crystal violet dye staining
assay.
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Induction of p21
Induction ofp21 WAF! gene by 60Cov-irradiation was used to assess p53 function. The
p53 wild-type cell line, LNCaP, expresses functional p53 as indicated by the
induction of the p21 target gene (Figure 8). No appreciable p21 induction was
apparent during the initial 2.5 hours post-irradiation but p21 induction reached a peak
7.5 hours post-irradiation (7Gy 60COy-irradiation).
No significant p21 induction was evident in the 1532T, 1535T, 1542T and 1542N cell
lines immortalised with the E6 and E7 transforming genes ofHPV-16, or the BPH-l cells
which have been immortalised with the large T-antigen gene of SV40. No p53 -
independent induction of p21 was evident either.
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Figure 8: The response of prostate cell lines to 7Gy 60Coy-irradiation in terms of
nuclear accumulation of p21WAF!
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Drug toxicity
Results from crystal violet assay data demonstrate that cell lines differ in drug
sensitivity. Using TD50 data the cell lines can be ranked as follows:
Etoposide: LNCaP>BPH>1532T>1535T>1542N>1542T
Vinblastine: LNCaP>BPH>1532T>1542N>1535T>1542T
Estramustine: BPH>LNCaP> 153ST>1542N> 1532T> 1542T
It is apparent that LNCaP is the most resistant cell line against vinblastine and etoposide,
and the second most resistant against estramustine. The 1542T cell line is by far the most
sensitive cell line against all 3 drugs (Figure 9, Table 2).
Vinblastine is the most toxic drug with TD50 values ranging from 0.15 - 3.70oM.
Etoposide takes an intermediate position with TD50 values ranging from 0.15 -
4.70JlM, Estramustine is the least toxic drug shown by TD50 values ranging from
1.45 - 4,30JlM,
Table 2: TD50 drug concentrations for 6 human prostate cell lines,
Cell lines Etoposide (JlM) Vinblastine (nM) Estramustine (JlM)
LNCaP 4,70 3,70 3,90
BPH-l 0,70 3,34 4,30
1532T 0,57 0,29 l.76
1535T 0.45 0,26 2,51
1542T 0.15 0,15 1.45
1542N 0,39 0,28 l.85
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Figure 9: Dose response curves of estramustine, vinblastine and etoposide for 6
human prostate cell lines.
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DNA dsb repair capacity
DNA repair was assayed by constant-field gel electrophoresis which measures the
concentration of mobile (low molecular weight) DNA generated by double-strand
breaks after high doses of irradiation (l0-1OOGy). A typical gel is shown in Figure
10. Lanes 1 to 3 show DNA after OGy irradiation. The effect of irradiation dose on
DNA mobility after 10,20,40, 80 and 100Gy is shown in lanes 4 to 6, lanes 7 to 9,
lanes 10 to 12, lanes 13 to 15, and lanes 16 to 18, respectively. These results were
used to plot the dose-response curves.
The dose-response curves for initial (0 hour) and residual (after 2 hours and 20 hours
of repair) DNA damage are presented as a plot of the fractions of DNA released (Frei)
against irradiation dose (Figure 11). The areas under the initial damage curves (no
repair) range between 24.38 and 39.67. These results are summarised in Table 3.
To assess the rate of double-strand break repair, ratios of AUC values representing
initial damage versus residual damage after 2 hours and after 20 hours were
calculated. These results are summarised in Table 4. After 2 hours of repair, the six
cell lines show repair ratios (AUCo/AUC2) ranging from 1.70 - 3.83. The 20 hours
repair ratios (AUCo/AUC2o) range from 3.77 - 12.02.
After 2 hours DNA repair the more radioresistant cell lines, BPH-l and 1532T, (with SF2
values of 0.54 and 0.52, respectively) show higher levels of DNA dsb rejoining than the
more radiosensitive cell lines, LNCaP and 1542T. The 2 hours repair and radiosensitivity,
measured in terms of 0, were significantly correlated, giving a regression coefficient of r =
0.92 (p = 0.009) (Figure 12). Increases in the a coefficients would imply increased
sensitivity to radiation, and low repair proficiency. No relationship was apparent between
the 20 hours DNA repair capacity and radiosensitivity (Figure 13), and between initial
DNA damage and radiosensitivity (Figure 14). This indicates that, in terms of clonogenic
survival, radiosensitivity in these prostate cell lines is related to the fast (2 hours) DNA dsb
repair component, and not to the slow (20 hours) DNA repair component. The 20 hours
repair component has been found to be diagnostic of radiosensitivity in a wide variety of
tumour cell lines of different origin.
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Figure 10: CFGE gel showing DNA released for the dose range O-lOOGy in a single
prostate cell line.
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Figure 11: Dose response curves for initial (Ohr) and residual (2hr and 20hr) DNA
double-strand breaks in 6 prostate cell lines after 0-100Gy 60CO y-irradiation, as
determined by fluorescent densitometry of ethidium bromide stained CFGE gels.
Area under the curve (AVC) was calculated for each dose response curve and is given
in Table 3.
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Table 3: Areas under the dose-response curves (AVC) calculated from fractions of
DNA released, against irradiation dose, in the range 0-100Gy for Ohr, 2hr and 20hr
after irradiation (Figure 11), and radiosensitivity measured by the mean inactivation
dose, D, (area under survival dose response curve plotted on a linear-linear scale) for
6 human prostate cancer cell lines.
1532T 1535T 1542N 1542T BPH-l LNCaP
Initial DNA damage 33.94 39.67 30.66 30.72 24.38 33.41
2hr repair 8.86 14.33 10.62 16.61 8.07 19.70
20hr repair 7.26 10.51 7.05 6.97 3.79 2.78
D (Gy) 2.72 2.40 2.28 1.84 2.77 1.62
Table 4: Ratios of initial vs residual DNA damage derived from AVC data (Table 3)
for various repair times.
1532T 1535T 1542N 1542T BPH-l LNCaP
2hr repair 3.83 2.77 2.89 1.85 3.02 1.70
20hr repair 4.67 3.77 4.35 4.41 6.43 12.02
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Figure 12: Plot of DNA repair capacity as a function of radiosensitivity in 6 prostate
cell lines. Repair capacity is defined as the ratio of the area under the repair curve at
zero repair time, to the area under the repair curve after 2 hours of repair time.
Radiosensitivity is expressed as the mean inactivation dose, 0, which is given by the
area under the cell survival dose response curve, plotted on a linear-linear scale.
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Figure 13: Plot of DNA repair capacity as a function of radiosensitivity in 6 prostate
cell lines. Repair capacity is defined as the ratio of the area under the repair curve at
zero repair time, to the area under the repair curve after 20 hours of repair time.
Radiosensitivity is expressed as the mean inactivation dose, 0, which is given by the
area under the cell survival dose response curve, plotted on a linear-linear scale.
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Figure 14: Plot of initial (Ohr) DNA dsb damage induced by high doses of 60Co y-
irradiation, as a function of radiosensitivity in 6 prostate cell lines. Initial DNA dsb
damage was measured by the CFGE assay. Radiosensitivity is expressed as the mean
inactivation dose, D, which is given by the area under the cell survival dose response
curve, plotted on a linear-linear scale.
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Induction of apoptosis after drug exposure
The incidence of apoptosis in response to drug exposure, at TD50 concentrations, was
assessed over a period of 48 hours in 6 prostate cell lines, and can be ranked as
follows:
Etoposide: 1535T> 1532T> 1542T> 1542N>LNCaP>BPH-l
Vinblastine: LNCaP>1542T>1535T>1532T>1542N>BPH-I
Estramustine: LNCaP> I542N> I 542T> BPH-I>1532T>1535T
Apoptosis was found to be dose- and time-dependent in all cell lines. Apoptosis
levels ranged from 0.1 - 12.1%,3.0 - 6.0% and 0.1 - 8.5% for etoposide, estramustine,
and vinblastine exposures, respectively (Table 5). The BPH-l cell line yielded the
lowest percentage of apoptotic cells after exposure to a given drug dose of vinblastine
and etoposide. The LNCaP cell line yielded the highest percentage of apoptotic cells
after exposure to a given drug dose of vinblastine and estramustine. Estramustine
emerged as the least toxic drug for this panel of cell lines, showing low apoptosis
level with an upper range of 6.0%. Vinblastine, the most toxic drug employed in this
study, assumed an intermediate position with an upper apoptosis range of8.5%, whilst
etoposide showed the highest level, with an upper range of 12.1%. Maximum
apoptosis levels for the prostate cell lines occurred between 6 and 48 hours after
addition of the drug (Figure 15).
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Table 5: Percentage maximum apoptosis, measured by fluorescent microscopy, for 6
prostate cell lines exposed to TDso concentrations of etoposide, vinblastine and
estramustine over a period of 0-48 hours. The time of maximum expression of
apoptosis (in hours) for each cell line, versus each drug, appears in brackets.
Cell lines Etoposide Vinblastine Estramustine
LNCaP 4.4 (12h) 8.5 (24h) 6.0 (36h)
BPH-l 0.1 (24h) 0.1 (48h) 4.0 (12h)
1532T 8.0 (6h) 3.3 (12h) 3.6 (6h)
1535T 12.1 (6h) 4.0 (36h) 3.0 (24h)
1542T 6.0 (24h) 6.0 (36h) 4.8 (36h)
1542N 4.8 (12h) 3.1 (24h) 5.1 (12h)
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Figure 15: Percentage apoptosis induced in 6 prostate cell lines exposed to TD50
concentrations of etoposide, estramustine and vinblastine, over a period of 48hr. Each
data point was corrected for spontaneous apoptosis in untreated cultures incubated for
corresponding periods of time.
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Induction of apoptosis after 60Coy-irradiation
The percent apoptosis induced by doses of gamma irradiation resulting 10 50%
survival at 48 hours post-irradiation can be ranked as follows:
1532T> 1535T> 1542T> 1542N>BPH-l>LNCaP
The data for apoptosis shows a dose- and time-dependent occurrence of this
phenomenon in all cell lines.
Apoptosis levels ranged from 1.3 - 7%. The LNCaP cell line yielded the lowest
percentage of apoptotic cells after exposure. The 1532T cell line yielded the highest
percentage of apoptotic cells after exposure. Maximum apoptosis levels for the
prostate cell lines occurred at varying times between 6 and 48 hours. Figure 16 also
shows that apoptosis does not rank these cells according to radiosensitivity.
10.0
r.fl 7.5.-r.fle....c.
e 5.0c.e::
'iJ.
2.5
----- 1532T
---- 1535T
----1542N
--+-BPH-1
1542T
-o-LNCaP
o.0 -IF"::.........II---,.-------.---.-----,;---__;~------,
o 10 20 30 40 50 60
TIme after exposure to irradiation (hr)
Figure 16: Percentage apoptosis induced over a period of 48hr in 6 prostate cell lines
exposed to doses of 60Co y-irradiation resulting in 50% survival. Each data point was
corrected for spontaneous apoptosis in untreated cultures incubated for corresponding
periods of time.
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Expression of Bax and BcI-2: basal levels and the effect of DNA damage
Bax and bcl-2 expression was determined after etoposide, vinblastine and
estramustine treatment at TD50 concentrations. Samples were taken at the time of
maximum apoptosis expression and were then analysed for baxlbcl-2 expression.
Immunoblotting demonstrated that bax and bcl-2 proteins were expressed at a basal
level in all the cell lines, and that the levels, analysed by densitometry (UN-SCAN-
IT1M gel automated digiti sing system, Silk Scientific, USA), were unaffected by
exposure to etoposide, vinblastine and estramustine (Figures 17, 18, and 19).
Exposures to TD50 doses of etoposide, vinblastine and estramustine at the time of
maximum apoptosis did not change the bax/bcl-2 ratio. The bladder carcinoma cell
line, RT 4 (Chresta et al 1996), served as a positive control for both bel- 2 and bax
detection, using our antibody, and was run on the same gel.
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+ve 1542T 1542N 1532T
control control TD50 control TD50 control TD50
Bcl-2 ~ ~ ~~ ~ ~.. - . .. .;.!~ ,J; ::- ....1-
Bax
+ve 1535T LNCaP BPH-l
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Bcl-2
~~' W '~o£ ~~, ~ i~~ ,
Bax
Figure 17: Western blot analyses of apoptotic-related protein expression pre- and
post- TD50 etoposide treatment, in a panel of six prostate cell lines. The bladder
carcinoma cell line, RT4, served as the positive control.
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+ve 1542T 1542N 1532T
control control TD50 control TD50 control TD50
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Figure 18: Western blot analyses of apoptotic-related protein expression pre- and
post- TD50 vinblastine treatment, in a panel of six prostate cell lines. The bladder
carcinoma cell line, RT4, served as the positive control.
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Figure 19: Western blot analyses of apoptotic-related protein expression pre- and
post- TD50 estramustine treatment, in a panel of six prostate cell lines. The bladder
carcinoma cell line, RT4, served as the positive control.
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CHAPTER4
DISCUSSION
1. Drug resistance in prostate cancer eeUlines is influenced by androgen
dependence and p53 status.
The human prostate cell lines, DU145, PC-3 and LNCaP, originate from metastatic
lesions (Stone et a11978, Kaign et a11979, Horoszewicz et aI1983). These cell lines
are in common use and represent the most widely used cell biological model. A
model which is closer to clinical reality would be epithelial prostate cultures which
reflect the in situ characteristics of normal epithelium, the epithelium of benign
hyperplasia, and the malignant epithelium (Hayward et al 1995, Bright et al 1997).
Cell lines derived from normal, BPH and cancer tissue were chosen to cover the range
from non-prostatic disease through to prostatic cancer. The possibility that prostate
cancer may arise from prostatic hyperplasia is still controversial (Kirby et al 2001).
Prostate cancer most commonly arises within the peripheral part of the prostate, while
BPH predominantly develops within the transition zone. However, it has been
reported that patients with BPH have a much greater risk of developing prostate
cancer than men without BPH (Armenian et aI1974). On the other hand, there is no
clear evidence that BPH is a direct precursor of adenocarcinoma (Kirby et al 2001).
Nevertheless, a cell line such as BPH-l can serve as an acceptable model for the
transformation of a non-tumorigenic prostatic epithelium to a tumorigenic phenotype.
The cell lines grow in the absence of foetal bovine serum (PBS), with or without 50.-
dihydrotestosterone (DHT) supplementation, at rates comparable to that in the presence of
serum. It is apparent in Figure 7 that LNCaP cells respond to DHT stimulation and hence
are androgen sensitive. This is consistent with published data (Horoszewicz et aI1983). It
is also evident that all the transformed cell lines are androgen independent. The
differences in growth between the FBS-cultures and the charcoal-stripped (cs)FBS-
Stellenbosch University http://scholar.sun.ac.za
56
cultures may be attributed to the removal of substances, other than steroids, which are
essential for growth. This is in agreement with the observation that the addition of the
synthetic androgen, methyltrienolone (Bright et al 1997) can restore cell growth after
charcoal stripping of the growth medium. The rationale for determining the hormone
status was to confirm that androgen sensitivity was not lost in culture. Janssen and
colleagues elaborated on this problem (Janssen et a11995).
As expected, cell inactivation, measured by crystal violet assay, was drug and
concentration dependent (Figure 9, Table 2). The crystal violet assay is well
established to measure the toxicity of radiation and chemotherapeutic drugs. Using
tritiated thymidine to inactivate background cell population, the surviving fraction of
established cell lines measured over a dose range of 0-6Gy by the standard clonogenic
assay is in close agreement with results obtained with the crystal violet assay (Baker
et al 1986). The differential response of cell lines to the same drug could be due to
multi drug resistance (MDR). The following patterns can be distinguished: the 1542T
cell line is the most chemosensitive, and the LNCaP cell line is the most
chernoresistant. I speculate that the greater chemosensitivity of LNCaP cells against
estramustine, as compared to BPH-l cells, may be due to an androgen-suppressing
effect of this drug. Interestingly, the 1542N cell line appears more resistant to
vinblastine, etoposide and estramustine, than its tumour counterpart, 1542T (Figure
9). Unlike Berchem et al (1995) and Raffo et al (1995) the transition of prostate
cancer cells to a hormone independent state was not found to generate
chemoresistance. The results clearly demonstrate that the hormone independent cell
lines are the most chemosensitive (Figure 9, Table 2). Estramustine proved to be the
least toxic agent. This is in agreement with other studies showing that estramustine
has no significant single-agent activity in hormone-refractory prostate cancer
(Speicher et al 1992, Pienta et al 1996). However, there is in vitro evidence that a
combination of estramustine and taxol, or estramustine and etoposide, has a supra-
additive cytotoxic effect on prostate cancer cells (Speicher et a11992, Pienta and Lehr
1993). Clinical studies have now demonstrated the efficacy of these combinations in
phase 2 trials using estramustine plus vinblastine, etoposide, docetaxel and paclitaxel
(Dimopoulos et a11997, Smith et a11999, Petrylak et aI1999).
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In the LNCaP cell line it has been demonstrated that androgens are capable of
inducing resistance to chemotherapy in a bcl-2-dependent manner (Berchem et al
1995). In a previous study in a panel of prostate cell lines I have shown that
chemoresistance is linked to androgen dependence (Serafin et aI2001).
Drug-induced cell inactivation often invokes programmed cell death or apoptosis
(Reed 1997). Model systems have demonstrated that factors which influence the
apoptotic pathway can confer relative resistance to cytotoxic agents (Karnesaki 1993).
In this scenario the apoptosis inhibiting bcl-2 gene product (Eliopoulos et al 1995,
Reed 1997, Mackey et al 1998) would be of interest as a role player in cell toxicity.
A major factor in the cellular damage response is the p53 tumour suppressor gene.
Evidence for a link between the growth suppressing activity of p53 and the
inactivation of cyclin-dependent kinases has been provided by the cloning of the
WAF l/CIP I gene (p21), the transcription of which is directly activated by p53.
Expression of WAFl/CIPl in mammalian cells inhibit cell growth, suggesting that
p21 is a downstream mediator ofp53 function (EI-Deiry et aI1993). It has also been
shown that WAFl/CIP1 is induced by DNA damaging agents that trigger G] arrest or
apoptosis in cells with wild-type p53 but not in tumour cells where p53 is mutated or
deleted (EI-Deiry et aI1994). Michieli et al (1994) have suggested the existence of
two separate pathways for the induction ofW AFl/CIP1, a p53-dependent one elicited
by DNA damage which leads to growth arrest, and a p53-independent one triggered
by growth factors associated with cell growth. It is clear, therefore, that p53 status is
important and that factors which influence the functionality of this gene need to be
considered.
The establishment and maintenance of stable human prostate epithelial cell lines from
primary tumours has met with difficulties in the absence of in vitro immortalisation
(Schwab et aI2000). The 1532T, 1535T, 1542T, 1542N and *BPH-l cell lines were
immortalised by transduction with a recombinant retrovirus encoding the E6 and E7
genes of human papilloma virus serotype 16 (HPV -16), or the *large T antigen gene
of simian virus 40 (SV40). Expression of the E6 gene results in cellular
immortalisation through inactivation of the p53 growth suppressor protein, whereas
expression ofE7 destabilises retinoblastoma (Rb) protein, and activates telomerase to
maintain telomeres in the chromosomes (Coursen et al 1997, Somasundaram 2000).
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The SV40 large T antigen, in contrast, also abrogates the p53 and Rb pathways,
mediating both cellular immortalisation and transformation (Martin and Chou 1975).
The ability of SV40 large T antigen to induce transformation may be due to mutations
in other cellular genes not directly effected by the T antigen (Ozer et al 1996). The
transformation procedure may affect certain aspects of the cell phenotype, such as the
proliferation rate (doubling time), the ability to grow without serum or androgen
stimulation, the formation of colonies in soft agar, and the formation of tumours in
vivo (Schwab et al 2000). It is, therefore, not surprising that only the non virus-
transformed cell line, LNCaP, expressed functional p53 as indicated by the induction
ofp21 (Figure 8).
Recent data on Wi38VA13 cells have shown that p53 can be functional in certain
types of SV40 transformed cells (Werner et aI2001). An important conclusion of the
p21 data is that all virus-transformed cell lines (BPH-1, 1532T, 1535T, 1542T, and
1542N) show complete abolition of p53 function and not partial p53 inactivation by
incomplete complexation to the virus product.
The conclusion of the p21 controls and p53 functionality tests are that the p53-
defective cell lines emerge with superior sensitivity to vinblastine and etoposide. This
is evident from the low TDso data for etoposide and vinblastine (Table 2) which
demonstrate that the p53-defective cell lines are approximately 10 times more drug
sensitive than the LNCaP line in which p53 is intact.
The finding of superior drug sensitivity in p53 defective prostate cell lines is in
contrast to results on human colon cancer cell lines which have shown that p53
disruption rendered cells resistant to the antimetabolite, 5-fluorouracil (Bunz et al
1999). However, a definitive conclusion of the influence of the p53 degrading viral
proteins is not possible because it appears that the E6 protein has effects other than
those mediated by p53 inhibition (Klingelhutz et aI1996).
The androgen sensitive tumour line, LNCaP, emerges as 10 times less sensitive to
vinblastine and etoposide. It is furthermore indicated that estramustine does not
distinguish benign hyperplasia cells from prostate tumour cell lines. Regrettably,
most of the cell lines investigated here were androgen independent. Availability of a
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p53-defective androgen dependent tumour cell line could have expanded the drug
sensitivity assessment even further.
2. Studies on the influence of DNA repair on radiosensitivity in prostate
cell lines.
Ionising radiation induces various types of DNA damage, such as double-strand
breaks (dsb), single strand breaks (ssb), base damage and DNA protein erosslinks
(Arrand and Michael 1992). The major factors determining radiosensitivity in human
tumour cell lines are DNA dsb induction and repair (Ruiz de Almodovar et al 1994,
Nunez et al 1996, Karran 2000). Differences in DNA repair proficiencies are widely
known to affect cellular radiosensitivity (Hu and Hill 1996, Britten et a11997, Dolling et al
1998).
Using SiX prostate cancer cell lines, varying m radiosensitivity from a mean
inactivation dose of l.62 - 2.77Gy, I show that the initial level of DNA damage per
unit dose is cell line dependent. This is consistent with other data showing that the
induction of DNA dsb varies widely between cell lines (Smeets et al 1993, Ruiz de
Almodovar et al 1994, Roos et al 2000). Some studies have suggested that no
correlation exists between radiosensitivity and repair of double-strand breaks (Smeets
et a11993, Olive et aI1994). High dose work (O-lOOGy) on AT2BE, NF, RIR, CRO,
CHO-Kl, xrs1 and xrs5 human and rodent cell lines, has demonstrated a relationship
between radiosensitivity and the number of unrepaired dsb (Smeets et al 1993,
Dikomey et al 1998). At low dose (0-10Gy), radiosensitivity correlates with the
initial DNA damage (Roos et al 2000). The absence of unrepaired DNA dsb
measured by the constant field gel electrophoresis (CFGE) assay gives no information
about the quality of the repaired DNA because mutations and misrepair are not
detected by the CFGE method and will feature as repaired DNA (although loss of
clonogenicity may ensue later). I demonstrate here for 6 prostate cell lines that a good
correlation exists between the 2 hour DNA repair and radiosensitivity, and that the
more radioresistant cell lines show better repair competence (Figure 12). No
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dependence of radiosensitivity on 20 hour DNA repair could be demonstrated (Figure
13).
Since the majority of the cell lines were androgen independent there was little point in
conjecturing about the role of androgen dependence in the correlation between
radiosensitivity and repair. The hormone sensitive LNCaP line fits the 2 hour repair
correlation. When the LNCaP data was removed from the plot, it emerged that the 2
hour correlation still applied, albeit at a lower correlation coefficient (r = 0.88 and p =
0.052), whereas the 20 hour correlation deteriorated (r = 0.550 and p = 0.337). DNA
repair consists ofa fast component (2-3 hours) during which the bulk of the DNA is
repaired by non-homologous end-joining (NHEJ), and a slow component which is
completed 16-24 hours after irradiation (Dikomey et aI1998), therefore 2 hour and 20
hour time points were chosen to examine the correlation between DNA repair and
radiosensitivity. In the 6 prostate cell lines studied here, the G2 block maximum is
reached 12-42 hours after irradiation, and an additional 24-60 hours plus are required
for the G2 block to resolve. While G2 checkpoint activation and repair may be
interrelated, a definite requirement of a G2 block as a repair facilitator is not obvious.
My findings are at variance with results on a variety of rodent and human cell lines
which show that radiosensitivity is correlated with 20 hour DNA repair (Dikomey et
al 1998, Theron et al 2000). Within the limitations of a cell biological model this
highlights the different behaviour of prostate tumour cells in terms of recovery from
DNA damage. That recovery from DNA damage can be successfully exploited by
drugs has been demonstrated for DU145, BM1604 and LNCaP cells which show a
markedly enhanced sensitivity to cisplatin, vinblastine and etoposide, when the drugs
are given under conditions of G2 block abrogation (Serafin et al 2001). This staging
of irradiation to produce a G2 block followed by cytotoxic drugs given with a non-
toxic G2 block abrogator (Pentoxifylline) forces cells into mitosis and hence to change
repair mode from homologous recombination (HR) in G2 to non-homologous end-
joining (NHEJ) at Gr. Results on caffeine, which is closely related to pentoxifylline,
have now demonstrated that the HR repair process is specifically inhibited (Asaad et
aI2000).
DNA damage induces the p53 tumour suppressor protein (Lee and Bernstein 1995).
When wild-type p53 cells are damaged by irradiation the increase of p53 protein
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causes a G) arrest and cells enter repair or apoptosis (Lee and Bernstein 1995). P53
mutant cells present in the majority of tumours show a G2 cell cycle arrest which
facilitates DNA repair and prevents the propagation of the defective genome to
daughter cells (Maity et al 1997). The downstream effects of p53 have lead to
contradictory hypotheses regarding the influence of p53 on radiosensitivity (Bristow
et al 1996). For example, p53 wild-type cells could initiate apoptosis leading to cell
death, and cells also could show a G, and/or G2 arrest and increase of DNA repair
leading to increased cell survival. P53-dependent apoptosis and G2 arrest, followed
by DNA repair and cellular recovery, appear to be controlled by different pathways
which operate differently between cell types (Morgan and Kastan 1997). Except for
the p53 wild-type LNCaP cells (Horoszewicz et aI1983), the cell lines used here were
immortalised with the large T-antigen of the simian virus 40 (BPH-1) (Hayward et al
1995), and with the E6 and E7 genes of the human papilloma virus 16 (1532T, 1535T,
1542T and 1542N) (Bright et a11997) and thus are p53 dysfunctional.
My results are in agreement with the general notion that cell death mainly results from
DNA double-strand breaks (Frankenberg-Schwager 1989). Interestingly, however, it
is apparent for this range of prostate cell lines that cellular radiosensitivity correlates
with the number of dsb measured within 2 hours of irradiation. Results on head and
neck squamous carcinoma tumour cells, HNSC, SCC, JSQ, and SQ also show this
correlation (Schwartz et aI1988). The fact that the 2 hour repair period can separate
radiosensitive from radioresistant cells in 2 groups of human tumour cell lines has
implications for therapy, and would be consistent with the clinical observation that
prostate tumours can be successfully controlled by low dose rate-brachytherapy
(Raqde et al 1998).
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3. The influence of pS3 and baxlbcl-2 on chemosensitivity in benign
and malignant prostatic cell lines.
P53 status is an important determinant of tumour responsiveness to antineoplastic
agents (Lowe 1995, Chresta et al 1996, Wilson et al 1997). I have assessed the role
of p53 and baxlbcl-2 in drug- and irradiation-induced apoptosis in 6 prostate cell
lines. It has been noted that loss of p53 function leads to resistance to chemotherapy
(Weller 1998, Keshelava et aI2001), and to radiation therapy (O'Connor et aI1993).
I determined p53 function by measuring induction of p21 in the prostate cell lines in
response to 7Gy 60Co y-irradiation. The p53-inactivated cell lines, 1532T, 1535T,
1542T and 1542N, are shown to exhibit enhanced sensitivity to etoposide and
vinblastine (to a greater degree), and estramustine (to a lesser degree), compared with
the p53 wild-type cell line, LNCaP. The BPH-l cell line responded well only to
etoposide. This result is in agreement with research showing that inactivation of p53
enhances sensitivity to multiple chemotherapeutic agents (Hawkins et al 1996, Wahl
et al 1996). There may be several explanations for the conflicting results.
Immortalisation of cell lines with human papilloma virus (HPV-16) E6 and E7, and
simian virus 40 large T-antigen (SV40) results in inactivation of p53 (Martin and
Chou 1975, Morales et al 1999). This complicates the interpretation of experiments
on drug sensitivity because HPV -16 E6 has effects on cells other than those mediated
by p53 inhibition (Klingelhutz et al 1996). Furthermore, tumour cells may acquire
additional genetic abnormalities in the process of becoming. immortal (Masters 2000)
that result in drug resistance. The role of p53 in drug sensitivity could also be
dependent on the class of chemotherapeutic used. Finally, certain cell types may
display a predominant apoptotic response to chemotherapeutic agents, and this could
explain their relative sensitivity to drugs. Fan and colleagues showed enhanced
sensitivity to drugs in breast cell lines which express HPV -16, yet do not have a
predominant apoptotic response (Fan et aI1995).
The normal function of p53 includes cell cycle arrest at the G1 and/or G2 checkpoint
in response to DNA damage to facilitate DNA repair and cell recovery (Kastan et al
1991). P53 mutant, but not p53 wild-type, melanoma and squamous cell carcinoma
cell lines have been shown to undergo dramatic chemosensitisation under conditions
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of G2 block abrogation (Binder et al 2000). Similar enhancements of drug sensitivity
have been demonstrated for p53 mutant prostate cell lines when the G2 block is
abrogated (Serafin et aI2001). The results show that early entry into mitosis renders
these cells particularly drug sensitive. Recent work on the repair response of
irradiated XRCC2 and XRCC3 cells defective in HR-repair has highlighted the
increased sensitivity of HR repair in G2 to caffeine (Asaad et al 2000). In the p53
wild-type cells the proportion of Gs-blockcd cells which enter early mitosis is usually
lower than 50%. This means that only a smaller G2 population (approximately 20%)
enters the G1 phase. The lower toxicity enhancements observed in p53 wild-type cells
may be due to the lower population of Gs-blockcd cells (Serafin et al 2001).
Activation of p53 can also induce apoptosis, and several studies have linked wild-type
p53 with susceptibility of tumour cells to DNA-damaging anticancer agents (Lowe et
al 1994, Wilson et al 1997). The conflicting reports on the influence of p53 status on
chemosensitivity raises the possibility that different chemotherapeutic agents may
have different p53-dependent effects in different tumour cells (Mueller and
Eppenberger 1996).
Data from clinical studies demonstrate that tumour burden affects patient
performance; the greater the tumour burden, the less likely the response to treatment
(Crawford et al 1999). Thus, it may be beneficial to start chemotherapy early in the
disease. The slow development of prostate cancer may offer opportunities for early
application of chemotherapy, including patients with a rising PSA level (Smith et al
1999). However, it is generally agreed that chemotherapy is not effective in the
treatment of primary prostate cancer (CF Heyns, personal communication).
Evidence obtained in the last few years has established that cytotoxic effectiveness is
related to the ability of drugs to induce apoptosis (Hannun 1997). The apoptotic
program is controlled by a variety of genes, many of which are mutated and/or
dysfunctional in human cancers (McGill and Fisher 1997). An important example is
the p53 tumour suppressor gene and members of the bcl-2 gene family (Reed et al
1996, McGill and Fisher 1997). Exposure to etoposide, vinblastine and estramustine,
and morphological scoring of apoptosis after acridine orange staining, shows that
neither normal nor malignant prostate cells exhibit high levels of apoptosis at any time
point up to 48 hours. An increased level of apoptosis was observed in the malignant
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cells only for the drugs, etoposide and vinblastine. Similar results were obtained for
the same panel of cells at 60CO y-irradiation doses which result in 50% clonogenic
survival, in the 0-48 hours time window. Many groups have indicated that apoptosis
may be the primary mode of death following gamma-irradiation only in specific cell
types such as haematopoetic or lymphocytic cells, but not in stromal- or epithelial-
derived tissues (Kyprianou et al 1997, Tannock and Lee 2001, Sheridan and West
2001). Indeed, experiments using a new range of Ferrocene and Rhodium-Ferrocene
drugs on the 1542 range of prostate cell lines indicate that necrosis (or late apoptosis),
but not apoptosis, is the prime route of cell death induced by these drugs (Weber et ai,
unpublished data). Cisplatin, on the other hand, given under identical conditions
elicits a marked apoptotic response (Weber et ai, unpublished data). Akudugu et al
have shown that the expression of apoptosis and micronuclei is influenced by the
extent of DNA double-strand break repair within the first two hours after irradiation
and that cell lines which repair more damage in the first 2 hours (by NHEJ) express
more micronuclei and less apoptosis (Akudugu 2000). Attempts to alter apoptotic
indices in epithelial- and stromal-derived tissues have failed to affect clonogenic
survival, suggesting that whilst the apoptotic pathway may be intact in malignant
prostate cells, other death mechanisms may override this response following
irradiation (Bromfield et aI2003).
Since the apoptotic levels for both p53-functional and p53-non functional cell lines
were low, it is difficult here to make a case for p53 functionality in apoptosis. My
results are at variance with reports that human papilloma virus E7 renders cells
dramatically more sensitive to apoptosis in response to various genotoxins (Brown
and Wouters, unpublished data). It has been argued that p53 is not strictly required
for drug-induced cell death because at high drug doses all anticancer drugs induce
apoptosis (and other types of death) independently of p53. In fact, the contribution of
p53 to drug-induced apoptosis is influenced by a variety of factors, such as the nature
of the toxin, dose, tissue and mutational background of the tumour (Bunz et al 1999,
Wallace-Brodeur and Lowe 1999).
Susceptibility to apoptosis is modulated by a family of proteins that have homology to
conserved regions of the bcl-2 gene (Yin et aI1994). Apoptosis is promoted by some
of the bcl-2 homologues (bax, bak, bad, and bclXs) (Farrow et al 1995, Yang et al
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1995), whereas other members of the bcl-2 family (bcl-2, bclXj , and bag-l ) form
dimers with the apoptosis-promoters and inhibit their activity, hence suppressing
apoptosis (Reed 1994, Takayama et al 1995). It has been suggested that a high bel-
2/bax ratio may be a useful prognostic indicator for chemoresistance (Pepper et al
1997). In my own immunoblotting experiments no changes were detected in the
expression of either bax or bcl-2 in the six prostate cell lines, after etoposide,
vinblastine and estramustine drug treatment. This is in agreement with the findings of
Chresta et al (Chresta et al 1996), but differs from the data of Zhan et al (Zhan et al
1994). It is speculated that increases in bax and bcl-2 are cell type-specific.
It has been stated that much of the published evidence relating to the role of apoptosis
following treatment with radiation or anticancer drugs is indirect (Tannock and Lee
2001). The presence of various apoptotic markers are noted, and it is assumed,
implicitly or explicitly, that a cause and effect relationship exists between the
expression of these markers and loss of cell viability (Tannock and Lee 2001). Some
have found a positive relationship (Kramer et a11996, Tai et aI1998), and others have
not (Pereira et al 1997, Veronese et al 1998). The results presented here suggest that
apoptosis is not a major route of drug- or radiation-induced cell death in prostate cell
lines. From the kinetics in the 0-48 hours time window it appears unlikely that
increasing the post-treatment observation time to 96 hours (when the earliest
surviving elonogens can be detected) will reveal a correlation between reproductive
cell death and apoptosis. Indeed, several investigators have shown that changes
which affect the expression of genes that control apoptosis have no influence on
clonogenic survival (Kyprianou et a11997, Beale et a11998, Tannock and Lee 2001).
The major findings of this research are that the extent of apoptosis in the loss of cell
viability following anticancer drug or irradiation treatment is cell line- and drug-
dependent, and that the overall level of apoptosis induced by the three established
cytotoxic agents and 60CO y-irradiation is rather low. It therefore appears that major
cellular deterioration in prostate cells is not coupled to apoptosis. This is not entirely
surprising because high levels of apoptosis are usually associated with high cell
turnover such as cells of the lymphatic system. My conclusions are entirely consistent
with other recent findings (Brown and Wouters 1999, Tannock and Lee 2001, Steel
2001, Bromfield et al 2003) strongly suggesting that neither the p53 status nor the
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ability of the cells to undergo apoptosis plays a significant role in the sensitivity to
DNA-damaging agents.
4. Clinical implications of findings, and possible future avenues for
research.
Understanding of the role of apoptosis and other death pathways is of great
importance for cancer treatment. If anticancer drugs and radiation damage give rise to
either cell death or repair it would be of clinical interest to identify agents which
would select these pathways. For example, inhibition of the bcl-2 protein, or up-
regulation of the bax protein, might be used to increase killing of tumour cells.
Conversely, up-regulation of bcl-2 or other genes that protect against apoptosis might
be an important target for control of damage to normal tissue.
The success of radiation therapy in the treatment of prostate cancer would depend
upon the eradication of all tumour elonogens (ie. tumour stem cells) to suppress
unlimited cell proliferation. Failure to eradicate these elonogens will result in the re-
growth of the tumour after treatment (Wong and Hill 1998). The mode of clonogenic
cell kill following DNA damage would be important in defining new strategies for the
control of prostate cancer and the understanding of the processes following
radiotherapy. Clinico-pathologic studies have not succeeded to correlate altered
expression of the p53, p21, bax, bcl-2, and caspase apoptosis-related genes to
radiocurability (Rakozy et al 1998). This could be due to the existence of alternative
pathways of cell death which obscure analyses focussed on apoptosis (Akudugu and
Bohm 2001, Abend et aI2000). There is increasing evidence that apoptosis is not the
sole mode of cell death following radio- and chemotherapy in epithelial tissues
(Dewey et a11995, Olive et a11999, SteeI2001). Indeed, it has been suggested that
apoptosis may actually occur in a non-elonegenic population after DNA damage
(Tannock and Lee 2001), and that a permanent cell-cycle arrest or senescence-like
terminal growth arrest may also be a factor in determining prostate cell death
Stellenbosch University http://scholar.sun.ac.za
67
following radiotherapy (Schwarze et al 2001). A comprehension of the range of death
responses of prostatic tumour cells clearly is important for therapy as it sets event
/
markers which could be indicators of the success of cell inactivation.
Because inhibitors of Poly(ADP-ribose) polymerase (PARP) are able to potentiate the
cell killing effects of some DNA-damaging agents and to inhibit repair of induced
DNA strand-breaks, such compounds may enhance the anti-tumour efficacy of
radiotherapy or cytotoxic drug treatment. PARP is known to regulate chromatin
structure by poly-ADP-ribosylation of nuclear proteins, to facilitate DNA base
excision repair, and to contribute to cellular recovery. Using a PARP-inhibitor, a 30-
50% increase in radiosensitivity has been observed in vitro in human prostate cancer
cell lines (Schlicker et al 1999). It is conceivable that such agents could be effective
against prostate tumours and it may be worthwhile to investigate their efficacy in
prostate cell lines.
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CONCLUSIONS
The human prostate cell lines 1532T, 1535T, 1542T, 1542N, BPH-l and LNCaP were
used to assess the influence of p53 status, p53 functionality, androgen dependence,
DNA repair, apoptosis and apoptosis-related proteins in response to DNA damage
induced by chemotherapeutic drugs and gamma irradiation.
The results demonstrate that loss of p53 function and androgen independence is not
correlated with cellular resistance to vinblastine, estramustine and etoposide. The p53
functionally-inactive cell lines were also androgen independent, and are shown to be
the most sensitive to the three anticancer drugs. While this observation is at variance
with published work suggesting that p53 mutants are resistant to treatment, it may
well be that the effects observed here are cell line- and drug-dependent.
The six prostate cell lines were found to show differences in radiosensitivity. When
radiosensitivity expressed as mean inactivation dose (D) was compared with residual
DNA damage remaining after 2 hours and 20 hours of repair, it was found that
radiosensitivity is significantly correlated with the 2 hour DNA repair component,
showing a correlation coefficient of 0.92 (p = 0.009). The more radioresistant cell
lines were found to show better repair competence. Since only one of the human
prostate cell lines was androgen sensitive, no case could be made for the influence of
androgen on radiosensitivity and DNA repair capacity.
Analysis of the role of p53 and bax/bcl-2 in drug- and irradiation-induced apoptosis
suggests that neither the p53 status nor the ability of the cells to undergo apoptosis
plays a significant role in the sensitivity to DNA-damaging agents. The overall level
of apoptosis for both p53-functional and p53-non functional cell lines in response to
the three cytotoxic agents and 60CO y-irradiation was found to be in the range of 0.1-
12%, and is rather low. While it cannot be excluded that the apoptotic pathway
operates in malignant prostate cells, other death mechanisms may override this
response. The level of apoptosis in response to drug or irradiation treatment was
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found to be cell line- and drug-dependent. Immunoblotting failed to detect any
changes in the expression of either bax or bcl-2 in all six prostate cell lines after
treatment with etoposide, vinblastine and estrarnustine, and both proteins were
expressed at a basal level.
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